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ABSTRACT 
JOHN HICKS DUMAS III:  Myocardial Electrical Impedance as a Metric of Completeness 
for Radiofrequency Ablation Lesions 
(Under the direction of Stephen B. Knisley, Ph.D.) 
Radiofrequency (RF) ablation has emerged as a promising curative therapy for atrial 
fibrillation and other supraventricular tachyarrhythmias.  Most RF ablation procedures create 
a pattern of linear lesions that either isolate ectopic focal triggers or divide the atria into 
functional regions too small to sustain macroreentry.  It is thought that these linear lesions 
must be complete (i.e. both continuous and transmural) in order to block arrhythmic 
conduction and to avoid creation of a more proarrhythmic substrate.  Currently, most ablation 
endpoints employ pacing-based metrics of lesion completeness that rely upon active tissue 
properties and are therefore limited by transient or delayed effects of RF on conduction.  
Myocardial electrical impedance is a passive tissue property that may provide an alternative 
intraoperative metric that overcomes certain limitations of pacing-based endpoints.  Because 
RF ablation markedly alters the tissue, it was hypothesized that linear ablation lesions change 
myocardial impedance. 
Custom instrumentation and data acquisition software were developed to measure 
impedance using the four-electrode method.  Computer simulations were performed to 
determine the effect of electrode size on four-electrode impedance measurement.  Receiver 
operating characteristic analysis was used to assess the diagnostic accuracy of both resistivity 
and translesion stimulus-excitation delay to predict completeness of individual lesions.  
Lesions (n=50) were created in the ventricles of 18 Langendorff-perfused rabbit hearts using 
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a linear epicardial ablation probe.  Lesions were either continuous and transmural (n=25), 
noncontinuous (n=18), or nontransmural (n=7), which was verified histologically after 
staining with 2,3,5-triphenyltetrazolium chloride.  Subthreshold AC current (10 μA, 1 kHz) 
and four electrodes in a linear array across the lesion were used to measure magnitude and 
phase of the tissue impedance.  When a continuous and transmural lesion was produced, the 
resistivity increased 26-58 Ωcm (p<0.02).  When a noncontinuous or nontransmural lesion 
was produced, changes in resistivity were markedly smaller and did not reach statistical 
significance.  No changes in phase shift were found.  The resistive component of myocardial 
impedance may provide a useful intraoperative metric of lesion completeness for RF ablation 
procedures. 
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CHAPTER 1 
INTRODUCTION 
Project Overview 
Radiofrequency (RF) ablation has emerged as a promising curative therapy for atrial 
fibrillation and other tachyarrhythmias.  It is thought that the linear lesions created during RF 
ablation procedures must be complete (i.e. both continuous and transmural) in order to 
successfully terminate the arrhythmia.  Currently, most ablation endpoints employ pacing-
based metrics of lesion completeness that rely upon active tissue properties and are therefore 
limited by transient or delayed effects of RF on conduction.  Myocardial electrical impedance 
is a passive tissue property that may provide an alternative intraoperative metric that 
overcomes certain limitations of pacing-based endpoints.  Because RF ablation markedly 
alters the tissue, it was hypothesized that linear ablation lesions change myocardial 
impedance.  The present study tested this hypothesis using the four-electrode method in 
isolated rabbit hearts. 
Clinical Significance of Atrial Fibrillation 
Epidemiology 
In the United States, an estimated 2 to 2.5 million people have AF.1, 2  Estimates of 
overall prevalence of AF in the U.S. range from 0.89% 1 to 0.95%. 2  At age 40, the lifetime 
risk of AF ranges between 20% and 26% for the general population of the U.S.3 and Europe.4  
Even for healthy patients without congestive heart failure or prior history of myocardial 
infarction, the chance of developing AF is approximately 15%.3 
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Several studies have shown that prevalence and incidence of AF increase with age 
(Figure 1).1, 2, 4-8  The ATRIA Study reported that the prevalence of diagnosed AF in patients 
younger than 55 years of age was 0.1%.2  In patients older than 40 years of age, AF 
prevalence is 2.3% in the United States.1  In patients between 55 to 90 years of age, 
prevalence of AF is 3.3% in the United States1 and 5.5% in Europe.4  AF prevalence is 
approximately 9% in patients older than 80 years of age.2, 6  Prevalence of AF has increased 
in recent years and will likely continue to increase as the population ages.7, 9  By 2050, Go et 
al predict that the prevalence of AF will be 2.5-fold greater than it was in 2001.2 
Prevalence of AF may be underestimated due to asymptomatic AF and limitations of 
detection methods.10-12  Asymptomatic AF is sometimes discovered “accidentally” during 
routine examinations5, 13, but up to 60% of asymptomatic cases may not be detected.14  In the 
AFFIRM Study, Flaker et al reported that 12% of patients diagnosed with AF were 
asymptomatic.15  For patients with documented symptomatic AF, episodes of AF are 12 
times more likely to be asymptomatic than symptomatic.16  Other commonly used methods 
for arrhythmia diagnosis also have limitations that may lead to undetected AF.  In a study by 
Ziegler and Koehler, continuous 24-hour holter monitoring at yearly intervals failed to detect 
atrial fibrillation or tachycardia in 25% of patients with prior history of AF who experienced 
episodes averaging more than 1 hour per day during the year.17 
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Figure 1.  Age-related prevalence of atrial fibrillation in the United States 
and Europe. 
Mechanisms 
The mechanisms by which AF is initiated and sustained may be explained by one (or 
both) of two prevailing theories known as the multiple-wavelet hypothesis and automatic 
focus theory.18, 19  The multiple-wavelet hypothesis states that a combination of sufficient 
atrial mass, shortened refractory period, and decreased conduction velocity enables multiple 
reentrant circuits to be maintained in the atria.20, 21  This theory is especially relevant in the 
presence of preexisting cardiovascular disease or structural abnormality.  Automatic focus 
theory states that AF is initiated by premature beats originating from rapid-firing ectopic foci, 
which reports have found primarily near the ostia of the pulmonary veins and vena cava.22-25  
The mechanism described by this theory is particularly relevant to paroxysmal AF (i.e. self-
terminating), especially in the absence of any other cardiovascular conditions. 
An important factor related to the mechanisms of AF is the progressive nature of the 
arrhythmia.26  Paroxysmal AF can degenerate into persistent and then permanent AF due to 
structural and electrical remodeling that occurs during AF.  During the first few days of 
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pacing-induced AF, atrial refractory period is shortened and AF becomes more easily 
sustained, thus “atrial fibrillation begets atrial fibrillation.”27, 28  Over the same time period, 
atrial contractility is diminished, leading to atrial dilation.29, 30  It is important to note that in 
each of these studies by Wijffels et al and Schotten et al, the shortened atrial refractory 
period and the contractility loss were temporary and recovered after a few days of normal 
sinus rhythm.27-30  In those animal experiments, however, the pacing-induced AF lasted only 
a few weeks, whereas in humans, paroxysmal episodes of AF initiated by ectopic focal 
triggers is are not limited by a study protocol.  Therefore, in humans, paroxysmal episodes 
that occur with sufficient frequency over several months or years may actually cause these 
electrical and structural changes to become permanent.  Once permanent changes have been 
established, the atrial substrate fits the characteristics described by the multiple-wavelet 
hypothesis.  It is in this manner that paroxysmal AF originally caused by ectopic focal 
triggers may degenerate into persistent or permanent AF. 
Health Risks 
Stroke is the most significant immediate risk of AF for most patients.  According to 
data from the Framingham Study, approximately 15% of strokes are attributable to AF.8  
Stroke risk in AF increases with age, with up to 36% of strokes being attributable to AF in 
patients older than 80 years of age.6, 8  Though stroke risk is lower for lone AF (i.e. AF in 
absence of any other cardiovascular conditions), the risk nevertheless increases with 
advancing age.31  One reason for the increased stroke risk is blood stasis during AF, 
especially in the left atrial appendage.32  Furthermore, even in the absence of other 
cardiovascular disease, AF is associated with increased fibrinogen concentration, which 
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creates a prothrombotic state.33, 34  Silent strokes or transient ischemic attacks may account 
for the fact that patients with AF are more than twice as likely to have dementia.13, 35 
In addition to stroke risk, AF is associated with increased risks of mortality.5, 36  
Though AF is not immediately life threatening in most cases, mortality rates are nearly two 
times greater for patients with AF compared to those without AF, even after accounting for 
other cardiovascular conditions.5, 36  In the setting of ventricular dysfunction, the diminished 
hemodynamic function in AF can also exacerbate the progression of congestive heart 
failure.37, 38 
Even though asymptomatic AF frequently escapes detection, the risks of 
asymptomatic AF are nevertheless the same as those for symptomatic AF.13, 15  In fact, the 
risks may be even greater for patients with undiagnosed, asymptomatic AF because 
undiagnosed AF goes untreated and because most asymptomatic patients have persistent AF 
(long duration of arrhythmia).13-15 
Current Treatment Options for AF 
Cardioversion 
Electrical or pharmacological cardioversion is commonly used for recently 
discovered AF.18, 19  Direct-current cardioversion fails to convert approximately 10% to 20% 
of patients to normal sinus rhythm, even after multiple shocks.39, 40  Cardioversion is less 
successful for long-term freedom from AF.  In patients with persistent AF, up to 50% have 
recurrences within 6 weeks of an initially successful conversion.40 
Pharmacological Therapies 
Pharmacological therapy is often the first line of treatment for long-term management 
of AF.18, 19  The two primary strategies for pharmacological treatment are to control 
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ventricular rate (rate control) or to maintain sinus rhythm (rhythm control).  The rate control 
strategy uses beta blockers, calcium channel antagonists, or digoxin to control the ventricular 
rate without treating the underlying AF.  The rhythm control strategy uses antiarrhythmic 
drugs to maintain sinus rhythm. 
The presumed advantage of rhythm control over rate control is that maintenance of 
sinus rhythm improves ventricular filling, which in turn reduces stroke risk and improves 
quality of life.  In practice, however, the antiarrhythmic drugs for rhythm control are poorly 
tolerated by up to 40% of patients41 and can even be proarrhythmic.42, 43  Furthermore, many 
antiarrhythmic drugs are ineffective for maintenance of sinus rhythm.  In a study by Van 
Gelder et al, only 39% of rhythm control patients were in sinus rhythm after two years.44  
Although maintenance of sinus rhythm has been shown to decrease mortality, the adverse 
effects of antiarrhythmic drugs offset the benefit.45, 46  In a meta-analysis of 91 
antiarrhythmic drug studies for AF, Nichol et al concluded that the use of antiarrhythmic 
drugs does not decrease mortality compared with placebo.47  Mortality rates are no better for 
rate control than for rhythm control44, 48, but rate control drugs have fewer adverse side 
effects.49  Ultimately, neither rate control nor rhythm control provides a cure for atrial 
fibrillation and neither is particularly effective for prevention of recurrence.50  One fortunate 
aspect of both strategies is that they are typically accompanied by an anticoagulation 
regimen.  Anticoagulation therapy with warfarin has been shown to decrease mortality45, 51 
and significantly reduce stroke risk31, 52 in AF. 
Surgical Therapies 
Of the surgical techniques for treatment of AF, the Cox-Maze III procedure is 
considered the most effective and is widely regarded as the “gold standard” for curative 
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treatment of AF.53.  The Cox-Maze III procedure uses a series of linear incisions to create 
nonconductive scar tissue in a pattern that divides the atria into functional subunits too small 
to support macro-reentrant circuits.54, 55  During the procedure, the left and right atrial 
appendages are also excised.  Together, the linear lesions create a “maze” of conduction 
pathways that allow atrial contraction and preserve atrial transport function, but halt AF by 
preventing the maintenance of macro-reentrant circuits.54, 55  Restoration of atrial transport 
function and excision of the left and right atrial appendages minimize blood flow stasis and 
clot formation that can lead to thromboembolism and stroke. 
High success rates have been reported for the Cox-Maze procedure.  In the largest 
study, performed by Dr. Cox and colleagues, 99% freedom from AF was reported.56  Other 
studies have reported success rates ranging from 85% to 97%.57-60  One long-term study by 
Prasad et al reported 97% freedom from AF at an average of 5.4 years after the procedure.61.  
For approximately 70% to 80% of patients, freedom from AF is maintained without the use 
of antiarrhythmic drugs.60, 61  Furthermore, reported mortality rates for the procedure are less 
than 3% 56-60  In addition, the procedure is associated with reduction of stroke risk compared 
to other cardiac surgeries.32 
Despite high rates of freedom from AF, low mortality, and decreased dependence on 
antiarrhythmic medication, there are several significant drawbacks that have prevented 
widespread adoption of the Maze procedure.  The procedure is highly invasive, requiring 
median sternotomy and cardiopulmonary bypass.  The procedure is also complex and time-
intensive, requiring up to several hours to complete.  As a result, the Maze procedure is 
rarely performed as a standalone surgery.18  Other drawbacks include major complications 
that require additional surgical intervention, which have been reported to occur in 
 8 
approximately 5% to 23% of cases.57-59  Due to the invasiveness of the procedure, several 
days of postoperative hospitalization are required58, which increases the expense of the 
procedure. 
Ablative Therapies 
Early curative ablation therapies for AF originated with focal ablation of the 
atrioventricular node using direct current electrical shocks.62, 63  RF energy was later 
introduced as a safer alternative to direct current shocks.64-66  Atrioventricular nodal ablation 
controlled ventricular rate, but did nothing to halt AF.  Furthermore, ablation of the 
atrioventricular node necessitated pacemaker implantation.  Following the success of the 
“cut-and-sew” Cox-Maze III procedure, RF ablation techniques were developed to create 
linear lesions that modified the underlying arrhythmogenic substrate.67-69  With the promise 
of a curative AF therapy far less invasive than the surgical methods, this early work by 
Haissaguerre et al led to a veritable explosion of atrial ablation research.  In addition to RF 
energy, several other energy sources have been investigated, including microwave70-76, 
cryothermy77, 78, laser79-81, and high-intensity focused ultrasound.82-84  RF, however, remains 
the most commonly used energy source in clinical practice.85 
Currently, most RF ablation procedures use linear lesions either to isolate ectopic 
focal triggers 23, 86, 87 or to divide the atria into functional regions too small to sustain 
macroreentry.88, 89  RF catheter ablation procedures typically have higher rates of AF 
recurrence than the surgical Cox-Maze III procedure.  For example, pulmonary vein 
isolation, one of the more common catheter ablation procedures, is associated with 
recurrence rates between 9% and 48% within 9 to 18 months for paroxysmal or persistent 
AF90-96 and up to 90% for chronic AF.97   
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At present, RF catheter ablation is most effective for younger patients with 
paroxysmal AF and no structural heart disease.  Freedom from AF, however, may be 
overestimated due to asymptomatic AF and inadequate detection methods during long-term 
follow-up.14, 98, 99 
Lesion Completeness in Radiofrequency Ablation for Atrial Fibrillation 
Despite the reported clinical success of RF catheter ablation procedures, there 
remains considerable room for improvement.  In recent years, some investigators have voiced 
concern that endocardial catheter ablation procedures are far too extensive, ablating much 
more myocardium than necessary for long-term freedom from AF.100, 101  Extensive ablation 
may terminate AF simply because “dead atria do not fibrillate.”100  Ideally, an RF ablation 
lesion set should terminate AF while preserving maximal atrial transport function.90, 102  In 
order to simultaneously achieve both of these objectives, a carefully targeted approach is 
required. 
Requirement of Lesion Completeness 
It is thought that the linear lesions must be complete (i.e. both continuous and 
transmural) in order to block arrhythmic conduction103-105 and to avoid creation of a more 
proarrhythmic substrate.106, 107  When surgical incisions are used to create lesions, it can be 
reasonably assumed that the lesion lines are both continuous and transmural.  Catheter 
ablation has the advantage of being much less invasive, but it is difficult to verify 
completeness of lesion lines produced by catheter-based energy sources.102, 105  Current 
procedural endpoints for AF ablation employ pacing methods to assess conduction block 
across lesion lines 92, 108 or test for the inducibility 109 or noninducibility of AF.90, 91  
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Unfortunately, the predictive value of these metrics is limited by the occurrence of delayed 
conduction loss 110-112 or late conduction recovery 113 following ablation. 
Inaccurate methods to detect lesion completeness also expose patients to the risks of 
either overtreatment or undertreatment.  Undertreatment can necessitate repeat ablation 
procedures, which increases both risk of complications from surgical or catheter-based 
procedures and the expense of additional procedures.  Overtreatment, on the other hand, can 
result in unnecessary loss of atrial function and can lead to potentially life-threatening 
complications such as pulmonary vein stenosis114-116, atrio-esophageal fistula117, 118, or 
pericardial tamponade119, which are reported to occur in approximately 6% of catheter 
ablation procedures.120 
Limitations of Available Intraoperative Endpoints for Ablation 
Tests for inducibility or noninducibility of AF are provocative maneuvers that can 
cause can cause paroxysmal AF to progress to persistent AF.108  Although some investigators 
have reported improved outcomes for ablation procedures guided by inducibility tests109, 121, 
the long-term predictive value of these tests is questionable.122  Furthermore, the ablation 
procedure itself can promote a temporary proarrhythmic state123-126, which has been 
implicated as a possible mechanism for initial failure of the Cox-Maze procedure.127, 128 
Tests for conduction block across lesion lines can be hampered by the occurrence of 
delayed conduction loss.111, 112  Because lesions may take days or even weeks to develop into 
mature nonconductive scar129, lesions that may ultimately provide complete block can appear 
initially unsuccessful, leading to possible overtreatment.  Pacing-based measures of lesion 
completeness, even those guided by electro-anatomical mapping, also have limitations that 
preclude their use in certain patient populations.  For example, pacing methods are not 
 11 
possible in patients with chronic AF who are unresponsive to cardioversion 105 or in patients 
undergoing ablation concomitant with procedures requiring cardioplegia.  Although other 
ablation endpoints such as reduction of electrogram amplitude and increase of pacing 
threshold are sometimes used, these have limited ability to predict long-term procedural 
outcomes.107 
Myocardial Impedance as a Potential Metric of RF Lesion Completeness 
Advantages of Impedance Measurement 
Myocardial electrical impedance may provide an alternative intraoperative metric of 
lesion completeness that can overcome certain limitations of current ablation endpoints.  
Impedance may also provide a direct measure of the degree of injury to ablated tissue 
independent of transient loss of excitability or conduction.  Because impedance is a passive 
tissue property that can be measured during fibrillation or cardioplegia, it could potentially be 
used to evaluate lesion quality in a larger patient population than pacing-based endpoints. 
Physiological Basis for Expected Ablation-Induced Impedance Change 
Many physiological changes resulting from RF ablation may be responsible for 
change in impedance, both within and beyond the region of acute coagulation necrosis.  
Within the acute lesion, severe damage to the plasma membranes and microvascular 
endothelium130 prevents the maintenance of normal ionic gradients and thus alters tissue 
impedance.  Severe damage to gap junctions in the region extending up to 3 mm beyond the 
acute lesion border130 increases the resistivity of the intracellular space by disrupting the cell-
to-cell conduction pathways. 
Effects secondary to RF ablation, such as local ischemia, may also contribute to 
changes in impedance.  Damage to the microvasculature has been shown to reduce blood 
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flow by 48% in the region extending up to 3 mm beyond the border of the acute pathological 
lesion in canine ventricle.131  Acute ischemia has been correlated with a triphasic increase in 
myocardial resistivity.132, 133  Effects of ischemia, including depletion of ATP, decreased pH, 
and increased intracellular calcium concentration, cause gap junction resistance to 
increase.134-136  Intracellular calcium overload caused by hyperthermic injury at temperatures 
above 50°C137 may also contribute to increased gap junction resistance. 
The Four-Electrode Method for Impedance Measurement 
For impedance measurement, the four-electrode method is advantageous because it 
eliminates potential error-causing effects of electrode interfacial impedance that occur with 
two-electrode methods (e.g., unipolar or bipolar RF catheters).138  The four-electrode method 
has been established in previous studies to assess ischemic injury132, 134, 139 and cell-to-cell 
coupling133, 140-142 in myocardium and to assess electrical burn injury in skeletal muscle.143-145  
Other studies have shown that the four-electrode method can be used to differentiate between 
healthy, ischemic, and chronically infarcted myocardium.146-149 
The method employs a linear array of four electrodes that are either placed on the 
tissue surface or impaled into the tissue.  An applied electrical current (IA) is passed between 
the two outer electrodes and the resulting voltage (ΔV) is measured across the two inner 
electrodes (Figure 2).  The resistivity (ρ) of the tissue is then calculated by Ohm’s law with a 
multiplicative calibration constant (K) that is unique to the electrode array (Equation 1). 
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Figure 2.  Schematic of the four-electrode method for impedance 
measurement. 
 ߩ ൌ ܭ
∆ܸ
ܫ஺
 Equation 1 
 
 
  
CHAPTER 2 
FOUR-ELECTRODE METHOD FOR MEASUREMENT OF BIOLOGICAL IMPEDANCE 
Introduction 
The four-electrode method is often used for measurement of specific impedance in 
biological tissues.  In the following discussion, the term “impedance” will refer to specific 
impedance.  Although the theoretical basis of the four-electrode method is relatively 
straightforward for homogeneous media, the application of the method to biological tissues is 
much more complex.  This chapter covers the theoretical basis of the four-electrode method 
and some practical considerations for application of the method to biological tissues. 
Basic Principles 
When current is applied to a volume conductor, the resulting potential gradient is 
determined by properties of the conductor itself and of the electrodes.  If current is applied 
through two point electrodes located on the surface of a semi-infinite volume conductor that 
is homogeneous, isotropic, purely resistive, and bounded on one side by an insulating 
medium, then the potential gradient can be described by a rather simple formula (Equation 
2): 
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where Vx,y,z is the voltage at point (x,y,z), ρ is the resistivity of the volume conductor, IA is the 
applied current, and d1 and d2 are the distances, respectively, to each of the two electrodes.150  
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Figure 3 shows the potential gradient created when a 10 μA current is applied to an ideal, 
semi-infinite volume conductor with resistivity (ρ) of 200 Ωcm. 
 
Figure 3.  Potential distribution resulting from 10μA current (IA) applied 
via point electrodes to the surface of a homogeneous, isotropic, semi-
infinite medium with ρ=200 Ωcm.  The interelectrode distance is 6 mm.  
Upper panel shows the 3-dimensional potential distribution.  Lower panel 
shows a 2-dimensional slice along the electrode array axis. 
Consider now that this volume conductor is an ionic solution (e.g. saline) and that the 
electrodes used for current delivery are metallic.  In this case, the impedance associated with 
the electrode-electrolyte interface produces a voltage when current passes from the electrode 
to the medium; this polarization voltage is in addition to the half-cell voltage of the 
electrode.138, 151  If the same two electrodes are used for current delivery and voltage 
measurement (two-electrode method), this polarization voltage is added to the voltage drop 
 16 
through the volume conductor.  The polarization impedance depends on the electrode 
material, electrolyte material, current density, and frequency.  In practice, it is difficult to 
correct for polarization impedance in the two-electrode method. 
The four-electrode method virtually eliminates interfacial impedance errors by using 
separate pairs of electrodes for current delivery and voltage measurement.138, 147, 152, 153  Using 
an amplifier with high input impedance to measure the voltage further reduces the possibility 
of current flow across the interfacial impedance.154  Consider again the ideal volume 
conductor and point electrodes depicted in Figure 3.  Because the applied current and the 
voltage distribution in this ideal medium are known, it is theoretically possible to calculate 
resistivity using the voltage difference between any two points – provided the points do not 
lie on the same isopotential contour.  The most common configuration used in practical 
applications of the four-electrode method arranges the electrodes in a linear array.  The 
outermost electrodes (E1 and E4) in this linear array are typically used for current delivery 
and the innermost electrodes (E2 and E3) are used for voltage measurement.  Resistivity is 
calculated from the ratio of voltage to current, which is then multiplied by a scalar constant 
(K) that is a function of the electrode spacing. 
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Figure 4.  Potential distribution resulting from 10μA current applied via 
point electrodes E1 and E4 to the surface of a homogeneous, isotropic, 
semi-infinite medium with ρ = 200 Ωcm.  E2 and E3 are the voltage 
measurement electrodes in the four-electrode array.  Interelectrode 
distances a and b are 1 mm and 4 mm, respectively.  Top panel shows the 
3-dimensional potential distribution.  Middle panel shows a 2-dimensional 
slice along the electrode array axis.  Bottom panel shows the potential 
along the electrode array axis at the surface. 
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Consider a linear four-electrode array of point electrodes, where electrodes E1 and E4 
are used for current delivery and electrodes E2 and E3 are used for voltage measurement.  
The array is located on the surface of the ideal volume conductor as depicted in Figure 4 (top 
panel).  The array has fixed interelectrode distances: a from E1 to E2, b from E2 to E3, and c 
from E3 to E4.  Using Equation 2, the voltages at E2 and E3, respectively, are expressed by 
Equation 3 and Equation 4. 
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By superposition, an expression is found for the difference in voltage between E2 and 
E3 (∆VE2,E3,Equation 5): 
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Separating the constants and rearranging yields an expression for ρ (Equation 6), 
which contains the scalar constant K (Equation 7): 
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When the distance from E1 and E2 is equal to the distance from E3 to E4, the 
equation for K simplifies to (Equation 8): 
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When the electrodes are equally spaced, the equation for K simplifies to (Equation 9): 
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For the example shown in Figure 4, the interelectrode distances a and b are 1 mm and 
4 mm, respectively.  By Equation 8, the value of K for this array is 1.25π.  The 10 μA current 
applied via E1 and E4 resulted in a voltage difference of 5.1 mV between E2 and E3.  By 
Equation 6, the resistivity is 200 Ωcm, which is exactly equal to the value assigned in the 
model. 
Conceptual Models for Myocardial Impedance Measurement 
Unlike the ideal medium on which the theory for the four-electrode method is based, 
myocardium is heterogeneous, anisotropic, and finite in extent.  Application of the four-
electrode method for impedance measurements in myocardium and other tissues must 
therefore assume a conceptual model in order to interpret the results.155  Selection of an 
appropriate model depends upon the purpose of the measurement, upon the geometry of the 
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preparation, and upon the relative size of the electrode array compared to the anatomic 
structures of myocardium. 
On the cellular level, myocardium can be considered as a bidomain, in which 
intracellular and extracellular domains are separated by the cell membranes as depicted in 
Figure 5.  Each of these bidomain components is associated with its own unique electrical 
properties.  Both the intracellular and extracellular domains are thought to be almost purely 
resistive.  The impedance of the intracellular domain is dominated by the resistance of gap 
junctions that connect a network of intracellular compartments.156  Current flow between the 
domains is dictated by the resistive and capacitive properties of the membranes.  On an 
intermediate, multi-cellular level, the organization of myocytes into parallel fibers creates a 
directional anisotropy of impedance.  In both the intracellular and extracellular domains, the 
longitudinal impedance (along the fiber axis) is lower than the transverse impedance.  This 
creates a preferential pathway for current flow.  On an even larger scale, other anatomical 
features such as the rotation of fibers with depth157 and the presence of blood vessels further 
influence the current flow pathways.158  This rather heterogeneous structure is far removed 
from the idealized isotropic medium on which the theory for the four-electrode method was 
originally based. 
 21 
 
Figure 5.  Idealized current distribution between the intracellular and 
extracellular domains of cardiac tissue. 
For four-electrode impedance measurements in myocardium, there are four primary 
conceptual models: isotropic monodomain, anisotropic monodomain, isotropic bidomain, and 
anisotropic bidomain.155  All four of these conceptual models assume that the tissue is 
uniform.155  Each model is associated with different limitations, which may or may not be 
relevant depending upon the purpose of the measurement.  For example, if the purpose of the 
measurement is to obtain a highly accurate characterization of the tissue impedance for use in 
computational modeling, then it is necessary to use the most accurate model, the anisotropic 
bidomain.  If, however, the purpose of the measurement is simply to monitor tissue injury, a 
simpler model may be adequate under certain controlled conditions. 
The simplest model is the isotropic monodomain, which considers myocardium to be 
an idealized volume conductor similar to that shown in Figure 4.  In this scenario, the 
orientation of the electrode array relative to the fiber axis is random, and an “apparent” 
impedance value is obtained that reflects a weighted combination of the actual longitudinal 
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and transverse impedances of both domains.  Although the isotropic monodomain model 
does not yield the actual impedance values, it may still be useful in a clinical setting.  For 
instance, if measurements are taken both before and after a given treatment and the position 
of the array is held constant, then the difference between the two measurements will indicate 
changes resulting from the treatment. 
The anisotropic monodomain model differs from the isotropic monodomain only in 
that it takes into consideration the array orientation relative to the fibers.  In this case, distinct 
terms for the transverse impedance and longitudinal impedance are obtained.  Incorporation 
of anisotropy into the monodomain model, however, does not account for the individual 
contributions of the intracellular and extracellular spaces to the total impedance.  As was the 
case for the isotropic version, the anisotropic monodomain may still have clinical value 
despite its limitations. 
The isotropic bidomain is the simplest conceptual model that takes into consideration 
the individual contributions of the intracellular and extracellular domains to the total 
impedance.  In this case, it is assumed that the applied current is distributed between the 
intracellular and extracellular domains as shown in Figure 5.  Using this model, distinct 
values for intracellular impedance and extracellular impedance are obtained.  The assumption 
of isotropic impedance in both domains is valid for a special case of constrained geometry, 
the 1-dimensional cable.  For example, the cylindrical shape of isolated papillary muscles 
provides a convenient geometry for cable theory.140, 156, 158-160  In this special case, the 
isotropic monodomain model is valid because current flows primarily along the fiber axis 
and is distributed between the two domains. 
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The anisotropic bidomain model provides the most accurate representation of cardiac 
tissue, though it too is highly idealized.152, 155  Plonsey and Barr derived equations for the 
four-electrode method in an anisotropic bidomain that obtain longitudinal and transverse 
impedance values for both the intracellular and extracellular domains.152  It is important to 
note that the equations derived by Plonsey and Barr require the assumption of equal 
anisotropy ratios, meaning that the ratio of transverse to longitudinal impedance is the same 
for both domains.  It is not certain whether this assumption of equal anisotropy ratios is 
indeed valid in cardiac tissue.160, 161 
Practical Considerations for the Four-Electrode Method 
Validity of Assumptions for Four-Electrode Theory 
The underlying theory of the four-electrode method makes several assumptions about 
the electrodes and the volume conductor.  The validity of these assumptions must be taken 
into consideration for practical measurements of impedance in biologic tissues. 
The first assumption is that the medium under measure is of infinite extent.  This 
assumption may be valid if the electrode array is much smaller than the tissue under measure.  
In myocardium, the distribution of current between the intracellular and extracellular 
domains depends on the distance between electrodes.  When the distance between the 
current-delivery electrodes (E1 and E4) is less than one length constant (λ), or approximately 
0.5 – 1 mm, the current flow is limited almost entirely to the extracellular space.152  When the 
electrode spacing is greater than 5λ, the current flow is fully distributed between the 
intracellular and extracellular domains.152  Assuming that the length constant of the tissue is 
approximately 1 mm, the electrode spacing should be at least 5 mm in order to use the 
anisotropic bidomain model. 
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The second major assumption of the models is that the array consists of point 
electrodes.  This assumption may be valid as long as the point electrodes are small compared 
to the interelectrode distance.162  If this assumption is not valid, then the value of the constant 
K in Equation 6 is no longer determined solely by the electrode spacing.163  In this case, it is 
necessary to determine the value of K by calibrating in a sample with known impedance.  
Normal saline (0.9%), which has a known resistivity of 70 Ωcm at 25°C, is often used as a 
calibrating solution.  Because saline or any other ionic solution is an isotropic monodomain, 
it may not be appropriate to use a bidomain model for interpretation of tissue measurement.  
The effect of electrode size on apparent measured resistivity is discussed in Appendix 1. 
The third assumption of the models is that the impedance properties are uniform 
throughout the tissue.  For example, the anisotropic bidomain model implicitly assumes that 
all of the fibers are oriented in parallel, so that the longitudinal and transverse axes are the 
same at any two points in the tissue.  In real myocardium, however, the fiber axis rotates with 
depth by as much as 80° within the first few millimeters from the tissue surface.157  If the 
electrode array spacing is great enough for distribution into both the intracellular and 
extracellular spaces (>5λ, or approximately 2.5 – 5 mm), then the penetration depth of that 
array will include fibers with orientations varying by up to 80°.  In this case, the values 
obtained for the longitudinal and transverse impedances for in each domain may not be 
correct.  For large array spacing, the averaging of the longitudinal and transverse impedances 
caused by fiber rotation can make the anisotropy difficult to detect.134, 147, 164  For this case of 
large array spacing, it is appropriate to consider the isotropic monodomain model for 
interpretation of the results. 
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Frequency Dependence 
In biological tissues, the lipid bilayers that compose cell membranes add a capacitive 
element to the impedance of biological tissues.165-167  As a result of this membrane 
capacitance, the impedance of biological tissues is complex-valued and is dependent upon 
the frequency of the applied current.148, 149, 164, 167-170  Because current passes more easily 
through the membrane capacitance at higher frequency than at lower frequencies, the tissue 
impedance decreases with increasing frequency.168  At low frequencies (< 5 kHz), 
myocardial impedance is dominated by the resistive component.148, 163  Similarly, blood is 
almost purely resistive below approximately 100 kHz.171  The relationship between 
impedance and frequency can be altered by the pathological state of the tissue.  For example, 
the impedance spectrum for myocardial infarct scar is flatter and lower than that for healthy 
myocardium.149, 169 
Potential Sources of Error 
One significant source of error frequently encountered in biological impedance 
measurements is stray capacitance between the lead wires or between the sample and 
ground.138, 161, 163, 172, 173  As frequency increases, the effects of stray capacitance become 
increasingly significant.  A common method for reducing errors caused by lead capacitance 
is to limit the length of the leads from the electrodes to the amplifier.174  The use of coaxial 
cables as lead wires can exacerbate stray capacitance errors unless active shielding is 
implemented.173 
Another source of error comes from instability of half-cell potentials for the voltage 
measurement electrodes.  It is often assumed that the differential voltage between two 
electrodes cancels the half-cell voltages if the electrodes are identical in size, shape, and 
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material.  In practical measurements, however, contaminants can change electrode half-cell 
potentials, causing noise.138, 175  Although the four-electrode method virtually eliminates the 
effects of electrode polarization impedance, it does not alter the effect of the electrode half-
cell potentials.  Fortunately, the instability of half-cell potentials is typically manifested as 
DC drift, which can be removed by AC coupling the amplifier. 
Other potential sources of error are related to the tissue preparation itself.  One aspect 
of the tissue preparation that affects impedance is the temperature.  It has been reported that 
myocardial resistivity decreases with temperature by up to 2% per degree Celsius.164, 176  
With proper control of specimen temperature, effects of temperature are negligible in 
biological impedance measurements.  Errors may also be caused by surrounding or 
immersing the tissue in a low-resistivity medium, such as a saline bath.165, 177  Even a thin 
layer of saline on the tissue surface can have a significant effect on the measured 
impedance.177 
Conclusion 
The four-electrode method is often used for measurement of biological impedance, 
but several assumptions are required for proper interpretation of the results.  Although the 
theoretical basis of the method is straightforward for homogeneous isotropic media, the 
application to biological tissues is rather complex.  The assumptions of the conceptual 
models and the potential sources of error impose several design constraints on the 
instrumentation used for impedance measurements in biological tissues. 
 
  
CHAPTER 3 
DEVELOPMENT OF ELECTRICAL IMPEDANCE MEASUREMENT SYSTEM 
Design Overview 
The hardware and software used for impedance measurements were designed to 
operate in two different modes: impedance and translesion stimulus-excitation delay.  In both 
modes, the system was designed to acquire two signals from the same four-electrode array, 
with one signal being tissue voltage (or electrogram) and the other a monitor of applied 
stimulus current.  For the four-electrode impedance measurements, these signals were the 
current applied through electrodes 1 and 4 and the resulting myocardial voltage across 
electrodes 2 and 3.  For stimulus-excitation delay, the signals were the pacing stimulus 
applied via electrodes 1 and 2 and the bipolar electrogram from electrodes 3 and 4.  Different 
acquisition parameters (sampling rate, record duration, etc) were required for each 
measurement.  Hardware and software features were incorporated into the design in order to 
facilitate easy switching between modes.  The acquisition software was designed to allow the 
user to observe signals in real time and to save the acquired data using a custom file format.  
Data in these files was analyzed using a different program written for use with Matlab 
(Release 12, The MathWorks, Natick, MA). 
Hardware 
Four-Electrode Arrays 
Two different four-electrode arrays (A and B, Figure 6) were used in experiments.  
Because stimulus-excitation delay measurements required an electrode pair on viable tissue, 
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the interelectrode spacing between E2 and E3 was greater that between E1 and E2 and 
between E3 and E4.  Interelectrode spacing was similar for arrays A and B. 
Array A, shown in Figure 6, was constructed from Teflon-insulated silver wire with a 
diameter of 0.28 mm (California Fine Wire Company, Grover Beach, CA) mounted on a 
glass microscope slide with nonconductive epoxy.  The insulation was stripped from the end 
of each wire to expose 2 mm of silver.  The interelectrode distances for array A were 1.5 mm 
from E1 to E2, 9.0 mm from E2 to E3, and 1.5 mm from E3 to E4. 
Array B was constructed from four stainless steel ring electrodes and then mounted 
on the RF coagulation device (CS-1002, nContact Surgical Inc., Morrisville, NC) such that 
the array was perpendicular to the RF coil as shown in Figure 6.  The interelectrode distances 
for array B were 1.7 mm from E1 to E2, 14 mm from E2 to E3, and 1.7 mm from E3 to E4.  
An advantage of this array was that it allowed RF ablation and impedance measurements to 
be performed with a single probe, which simplified positioning and may be beneficial for 
intraoperative applications of this method. 
 
Figure 6.  Four-electrode arrays “A” (left panel) and “B” (right panel). 
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Stimulus Current Source 
Current for impedance measurements was provided by a linear stimulus isolator 
(A395D, World Precision Instruments, Sarasota, FL) controlled by a function generator 
(33120A, Hewlett-Packard, Palo Alto, CA). 
Electronic Circuit 
There were six major design constraints for the measurement circuit.  First, the circuit 
needed to operate in two modes (impedance and stimulus-excitation delay) that required 
measurement of both a stimulus current and a differential voltage.  Second, for impedance 
measurements, the amplifiers required identical frequency responses in order to avoid 
introducing any additional phase shift between the current and voltage signals.  Third, the 
amplifiers needed to have high input impedance in order to prevent current from flowing 
across the electrode-tissue interface of the voltage measurement electrodes; interfacial 
current flow would cause an error-causing interfacial voltage to be added to the signal.  
Fourth, the amplitudes of the output signals needed to be within the ±10-volt range of the 
analog-to-digital converter (DAQPad 6070E, National Instruments, Austin, TX), but large 
enough to maximize signal resolution.  Fifth, the current-monitoring amplifier needed to 
handle different stimulus types for the two operational modes: subthreshold sinusoidal 
current (10 μA, 1 kHz) for impedance and suprathreshold pacing pulses (1-10 mA, duration 
3-4 ms, interval 300-700 ms) for stimulus-excitation delay.  Finally, the circuit needed to 
allow the user to switch between the two modes without unplugging the four-electrode array.  
The circuit schematic is shown in Figure 7. 
In order to satisfy the requirements of high input impedance and identical frequency 
response, a pair of identical isolation amplifiers (AD210AN, Analog Devices, Norwood, 
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MA) with 1 TΩ input impedance was selected.  Matched resistors were used to configure 
both amplifiers for identical gain (G=100).  The AD210 amplifiers use a 50 kHz carrier 
frequency in the isolation stage that was found to introduce high-frequency noise in the 
output signals.  Because of this 50 kHz noise, both of the output signals were passed through 
unity-gain buffer amplifiers and then through identical low-pass RC filters (cutoff frequency 
16 kHz) before the analog-to-digital converters. 
A key feature of the design is that it uses a single pair of amplifiers for both 
measurement modes.  In both modes, one amplifier measured the tissue voltage while the 
other amplifier monitored current by measuring the voltage across a precision resistor placed 
in series with the current source.  Because the stimulus current for the two modes differed by 
two to three orders of magnitude (10 μA vs 1-10 mA), the value of the current-monitoring 
resistor was 1 kΩ for impedance and 10 Ω for stimulus-excitation delay.  Because each mode 
required a different current-sensing resistor and a different combination of electrodes for 
current application and voltage measurement, an 8-pole, 6-position rotary switch was used to 
switch between modes.  This feature enabled the user to change the measurement mode 
without changing connections for the current sources or electrodes. 
The circuit was built on a printed circuit board that was designed using ExpressPCB 
software (Express PCB, Santa Barbara, CA).  Once all circuit components were installed, the 
circuit board was mounted in the enclosure shown in Figure 8. 
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Data Acquisition Software 
The data acquisition program was a virtual instrument (VI) written in LabVIEW 
(version 6i, National Instruments, Austin, TX).  The data acquisition board used for this 
particular application was a DAQPad 6070E (National Instruments), though program could 
also be used with other acquisition boards made by the same manufacturer.  Although 
measurement of impedance and stimulus-excitation delay required different acquisition 
parameters (e.g. sample rate, record duration, etc), the function of the program is the same for 
both modes.  The following description applies to both measurement modes unless otherwise 
noted. 
User Interface 
The user interface, known in LabVIEW as the “front panel,” is shown in Figure 9.  
The front panel includes user inputs as well as plots and numerical values for the acquired 
data.  A tabbed control in the upper left corner allows the user to select the measurement 
mode.  The tabs contain controls for acquisition parameters: input range, channel range, 
sample rate per channel, number of samples to read per scan, and number of scans to be held 
in the buffer.  Each tab contains the default acquisition parameters for the associated 
measurement mode, but the values may be changed by the user if necessary.  Located 
immediately below the tabbed mode-selection control is a text box that allows the user to 
enter comments to be saved in the header of the data file.  To the left are data plots that are 
updated in pseudo real time, depending on the scan rate and buffer size.  The program uses a 
circular FIFO (first in, first out) buffer that holds in memory all of the data displayed in the 
plots.  The program runs continuously until the user presses the “STOP” button located 
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immediately below the user comments box, at which time, all data in the buffer is saved to a 
data file. 
Block Diagram 
In LabVIEW, the “block diagram” is used to control the program flow.  In this 
program, the block diagram is divided into two frames.  The first frame, shown in Figure 10, 
controls the data acquisition and then sends the data to a second frame, shown in Figure 11, 
where it is saved to file using a custom file format.  When the user initiates data acquisition, 
the program starts in the first frame.  The acquisition parameters for the selected mode are 
passed to a sub-VI (subroutine) that configures the data acquisition board for the appropriate 
parameters.  The acquisition parameters are then passed to a frame that sets plot axes and 
initiates global variables.  After that step, the program initiates data acquisition and enters a 
loop that fills the FIFO buffer.  The loop terminates when the user presses the “STOP” button 
on the front panel or when an error occurs.  When that loop terminates, the data is passed to a 
conditional loop that calculates signal amplitudes, resistivity, and phase shift if impedance 
data is being acquired.  Once all steps in the first frame have been completed, the data is sent 
to the second frame to be saved to file. 
In the second frame of the block diagram (Figure 11), a file header is created and the 
data is converted into an array of 16-bit integers.  The header includes all of the acquisition 
parameters as well as any comments entered by the user.  A pop-up window gives the user a 
final opportunity to amend the comments before saving the file.  Once the data is converted 
and the header is created, a file dialog opens for the user to select a filename.  After a suitable 
filename has been selected, the header and binary data are written to the file. 
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Figure 9.  User interface for data acquisition program. 
 
Figure 10.  LabVIEW block diagram, frame 1 of 2. 
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Figure 11.  LabVIEW block diagram, frame 2 of 2. 
Data Analysis Program 
Analysis of all data files was completed using a program written in Matlab.  This 
program (Appendix 2) was written to read the custom data file format and to analyze data 
both for impedance recordings and for stimulus-excitation delay recordings.  Information in 
the file header identifies the measurement mode so that the appropriate analysis is performed.  
The following description applies only to the analysis of data for impedance measurements. 
The amplitudes of and phase shift between the sinusoidal current and voltage 
waveforms were determined using both time-domain and frequency-domain methods.  
Current and voltage amplitudes used for calculation of resistivity were determined in the time 
domain by taking the average of RMS amplitudes over 50 consecutive 1-ms segments.  In the 
frequency domain, the bins in the FFT power spectrum between 980 and 1020 Hz were used 
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to estimate power of the 1 kHz component.  The amplitude was taken as the square root of 
the estimated power. 
Phase shift was determined in the time domain by signal-averaging 50 consecutive 1-
ms segments for each signal, finding the time lag between current and voltage, and 
converting from ms to degrees.  Phase shift was determined in the frequency domain by the 
difference between the current and voltage phase spectra at 1 kHz.  Negative phase shift 
values indicate voltage lags behind current.  Resistivities and phase shifts determined by the 
time domain method were essentially identical to those obtained using the FFT method.   
Calibration 
Linearity 
Linearity of the impedance measurement system was verified using precision resistors 
ranging in value from 0Ω to 2000Ω.  Over the range relevant to myocardial measurements 
(0Ω-500Ω), measured values were within 3% of actual resistor values (Figure 12). 
 
Figure 12.  Linearity of resistivity measurement system.  The solid line 
shows observed resistance and the dashed line shows the actual 
resistance. 
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Electrode Constant 
The calibration constant (K, Equation 1) for each electrode array was determined 
using normal saline (0.9%) with a resistivity of 70 Ωcm at 25°C in a plastic beaker (diameter 
70 mm, depth 65 mm).  The array was inverted and placed on the surface of the saline.  The 
value of K was determined as the ratio of the known saline resistivity to the measured ratio of 
voltage to current (Equation 1).  The value of K was 0.7085 cm for array A and 0.7064 cm 
for array B. 
 
  
CHAPTER 4 
LOW-FREQUENCY MYOCARDIAL ELECTRICAL IMPEDANCE INDICATES 
COMPLETENESS OF LINEAR LESIONS PRODUCED BY RADIOFREQUENCY 
ABLATION IN RABBIT HEARTS 
Introduction 
Radiofrequency (RF) ablation has emerged as a curative therapy for arrhythmias 
including atrial fibrillation, which affects 2.3% of the U.S. population older than 40 years1 
and is associated with significantly increased risk of stroke.5, 6  Currently, most cardiac RF 
ablation procedures use linear lesions to isolate or eliminate ectopic focal triggers23, 87 or to 
divide the atria into functional regions too small to sustain macroreentry.88, 89  It is thought 
that the linear lesions must be complete (i.e. both continuous and transmural) in order to 
block arrhythmic conduction103 and to avoid creation of a more proarrhythmic substrate.106, 
107 
Despite the clinical successes of RF ablation for atrial fibrillation, there remains a 
need for intraoperative verification of lesion completeness.105  Current procedural endpoints 
employ pacing methods to assess conduction block across lesion lines92, 108 or to test for 
inducibility109 or noninducibility of atrial fibrillation.90, 91  The predictive value of these 
metrics can be limited by the occurrence of delayed conduction loss111, 112 or late conduction 
recovery113 following ablation.  In addition, pacing-based methods may not be applicable 
during fibrillation or cardioplegia. 
Myocardial electrical impedance measured with the four-electrode method may 
provide an alternative intraoperative metric of lesion completeness that overcomes certain 
 39 
limitations of pacing-based endpoints.  In contrast to pacing methods, impedance is a passive 
tissue property that can be measured during fibrillation or cardioplegia.  For impedance 
measurements, the four-electrode method is advantageous because it eliminates potential 
error-causing effects of electrode interfacial impedance that occur with two-electrode 
methods (e.g., unipolar or bipolar RF catheters).138  The four-electrode method for impedance 
measurement has been established in previous studies to assess ischemic injury132, 134, 139 and 
cell-to-cell coupling133, 140-142 in myocardium and to assess electrical burn injury in skeletal 
muscle.143-145  Impedance can also differentiate between healthy, ischemic, and chronically 
infarcted myocardium147-149 and between venous and myocardial tissues.178  Since RF 
ablation markedly alters the tissue, it was hypothesized that linear ablation lesions change 
myocardial impedance.  The purpose of the present study was to test this hypothesis using the 
four-electrode method in isolated rabbit hearts.  Changes in resistivity (ρ) and phase shift (φ), 
the two complex components of impedance, were examined for complete, noncontinuous, 
and nontransmural linear RF ablation lesions. 
Methods 
Tissue Preparation 
Hearts from New Zealand White rabbits (n=18) were isolated in accordance with a 
protocol approved by the Institutional Animal Care and Use Committee of the University of 
North Carolina at Chapel Hill.  Rabbits were euthanized by aural IV injection of a solution of 
sodium pentobarbital (120 mg/kg) and heparin (1000 USP units).  Following injection, the 
level of anesthesia was verified by toe pinch and the heart was excised.  The heart was 
quickly washed in Tyrode’s solution containing 129 mM NaCl, 5.4 mM KCl, 1.8 mM 
CaCl2•2H2O, 1.1 mM MgCl2•6H2O, 26 mM NaHCO3, 1.0 mM Na2HPO4•H2O, 11 mM D-
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(+)-Glucose, and 0.606 μM Bovine Serum Albumin (A7030, Sigma-Aldrich, St. Louis, MO).  
The aorta was then cannulated on a Langendorff perfusion apparatus and perfused with 
Tyrode’s solution at a rate of 30 mL/min at 37.0±0.5°C.  The perfusate was bubbled with a 
mixture of 95% O2 and 5% CO2. 
Impedance Measurement System 
Four-Electrode Method 
The four-electrode method employed a linear array of electrodes (E1-E4) placed on 
the tissue surface.  An electrical current (IA) was applied via the two outer electrodes (E1 and 
E4) and the resulting voltage (∆V) was measured across with the two inner electrodes (E2 
and E3).  The resistivity (ρ) of the tissue was then calculated by Ohm’s law, where K is an 
electrode calibration constant determined empirically for each electrode array (Equation 10).  
Phase shift represents the temporal delay between the voltage and current signals. 
 ߩ ൌ ܭ
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 Equation 10 
Electrode Arrays 
Impedance measurements were performed with either of two different four-electrode 
arrays (A and B).  Array A, which was used in the first 7 hearts (17 lesions), was constructed 
from Teflon-insulated silver wire with a diameter of 0.28 mm (California Fine Wire 
Company, Grover Beach, CA) mounted on a glass microscope slide with nonconductive 
epoxy.  The insulation was stripped from the end of each wire to expose 2 mm of silver.  The 
interelectrode distances for array A were 1.5 mm from E1 to E2, 9.0 mm from E2 to E3, and 
1.5 mm from E3 to E4.   
 41 
Array B was used for the last 11 hearts (33 lesions).  This array was constructed from 
four stainless steel ring electrodes and then mounted on the RF coagulation device (CS-1002, 
nContact Surgical Inc., Morrisville, NC) such that the array was perpendicular to the RF coil 
as shown in Figure 13.  The interelectrode distances for array B were 1.7 mm from E1 to E2, 
14 mm from E2 to E3, and 1.7 mm from E3 to E4.  An advantage of this array was that it 
allowed RF ablation and impedance measurements to be performed with a single probe, 
which simplified positioning and may be beneficial for intraoperative applications of this 
method. 
 
Figure 13.  RF coagulation device with attached four-electrode array.  In 
both panels, impedance measurement electrodes are numbered 1-4.  Left 
Panel shows the underside of the RF coagulation device with the four-
electrode array attached.  Right Panel shows placement of RF device on 
heart.  Impedance measurements were taken with the four-electrode array 
located halfway between the atrio-ventricular groove and the ventricular 
apex. 
Instrumentation 
Custom-built hardware and software were used to record the applied current and the 
resulting voltage for impedance measurements.  The subthreshold sinusoidal current (10 μA, 
1 kHz) was generated by a linear stimulus isolator (A395D, World Precision Instruments, 
Sarasota, FL) that was controlled by a function generator (33120A, Hewlett-Packard, Palo 
Alto, CA).  To measure the applied current (IA), an isolation amplifier (AD210AN, Gain 100, 
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Analog Devices, Norwood, MA) sensed the voltage across a 1 kΩ precision resistor placed in 
series between the stimulus isolator and E1.  An identical isolation amplifier was used to 
measure the resulting voltage (∆V) across E2 and E3.  The signals then passed through unity-
gain buffer amplifiers and low-pass RC filters (16 kHz cut-off).  Both sinusoidal signals were 
digitized at 200 kHz for 50 ms with a 12-bit data acquisition board (DAQPad 6070E, 
National Instruments, Austin, TX) controlled by a custom software program written in 
LabVIEW (Version 6i, National Instruments).  
Calibration 
Prior to experiments with hearts, linearity of the impedance measurement system over 
several orders of magnitude was verified using precision resistors.  The calibration constant 
(K, Equation 10) for each electrode array was determined using normal saline (0.9%) with 
resistivity of 70 Ωcm at 25°C132 in a plastic beaker (diameter 70 mm, depth 65 mm).  The 
array was inverted and placed on the surface of the saline.  The value of K was determined as 
the ratio of the known saline resistivity to the measured ratio of voltage to current (Equation 
10). 
Experimental Protocol 
Lesion Creation 
Lesions were created using a 2-cm linear RF coagulation device (CS-1002, nContact 
Surgical) and a 480 kHz RF generator (800XP EPT-1000 XP, EP Technologies, Sunnyvale 
CA).  The unipolar RF electrode, shown in Figure 13, was held in place by suction (-400 
mmHg) and was referenced to a return electrode (area 15 cm2) that cradled the opposing side 
of the heart. 
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Lesions were located on the left ventricular free wall (LV), posterior septum (PS), or 
anterior septum (AS).  Two collinear applications of RF (15-20W, 15-30sec) aligned end to 
end were used to create each lesion.  Continuous lesions were created by slightly overlapping 
the two applications, while noncontinuous lesions were created by leaving space between the 
two applications.  Transmural and nontransmural lesions were achieved by adjusting the RF 
power and duration within the ranges specified above.  All lesions extended from the atrio-
ventricular groove to the ventricular apex, with the exception of gaps in noncontinuous 
lesions. 
Myocardial Impedance 
Recordings were taken 11±1.2 minutes before and 6.4±0.8 minutes after application 
of RF.  For each recording, the electrode array was oriented perpendicular to the apicobasal 
axis and placed midway between the atrioventricular groove and the ventricular apex.  For 
any individual lesion, the same electrode array was used for both preablation and 
postablation measurements. 
Examination of Lesions 
At the conclusion of each experiment, the heart was stained with a solution of 2,3,5-
triphenyltetrazolium chloride (TTC, Sigma-Aldrich; 2.1g TTC in 150mL normal saline) 
delivered by arterial perfusion.  The TTC demarcated lesion boundaries by staining viable 
tissue dark red.  Lesions were then bisected longitudinally and classified according to 
continuity and transmurality (Figure 14).  Complete lesions had no viable tissue between the 
endocardium and epicardium over any part of the lesion length.  Noncontinuous lesions had a 
viable gap extending from endocardium to epicardium.  Nontransmural lesions had a viable 
region between the lesion and the endocardium that spanned the entire lesion length.  Figure 
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14 shows representative examples of complete, noncontinuous, and nontransmural lesions 
stained with TTC. 
 
Figure 14.  Representative lesions stained with TTC to demarcate lesion 
borders.  Viable myocardium appears dark red in color, while nonviable, 
ablated myocardium appears pale.  Complete lesions were both 
continuous and transmural (top panel), while incomplete lesions were 
either noncontinuous (middle panel) or nontransmural (bottom panel). 
Data Analysis 
The amplitudes of and phase shift between the sinusoidal current and voltage 
waveforms were determined using Matlab (Release 12, The MathWorks, Natick, MA).  
Current and voltage amplitudes used for calculation of resistivity were determined in the time 
domain by taking the average of RMS amplitudes over 50 consecutive 1-ms segments and in 
the frequency domain from the FFT magnitude at 1 kHz.  Phase shift was determined in the 
time domain by signal-averaging 50 consecutive 1-ms segments for each signal, finding the 
time lag between current and voltage, and converting from ms to degrees.  Phase shift was 
determined in the frequency domain by the difference between the current and voltage phase 
spectra at 1 kHz.  Negative phase shift values indicate voltage lags behind current.  
Resistivities and phase shifts determined by the time domain method were essentially 
identical to those obtained using the FFT method.  The results shown were obtained using the 
FFT method. 
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All statistical analyses were performed using SAS 9.1.3 (SAS Institute, Cary, NC).  
The effects of lesion location, lesion creation order, and electrode array type on resistivity 
and phase shift were evaluated with factorial analysis of variance (ANOVA).  Paired t-tests 
were used to evaluate changes in resistivity and phase shift for each lesion type.  All results 
are expressed as mean ± standard error of the mean.  P-values <0.05 were considered 
significant. 
Results 
Lesion Geometry 
Of all lesions, 25 were complete, 18 were noncontinuous, and 7 were nontransmural.  
No lesions were both noncontinuous and nontransmural.  Lesions had a mean length of 
30.4±1.0 mm and mean width of 7.8±0.2 mm.  The mean depth was 4.3±0.2 mm for 
complete lesions, 3.1±0.3 mm for nontransmural lesions, and 3.4±0.2 mm for noncontinuous 
lesions.  Gap widths for noncontinuous lesions were 2.2±0.3 mm. 
Preablation Resistivity and Phase Shift 
Preablation resistivity for all lesion sites was 183±23.8 Ωcm (n=17) for array A and 
135±5.6 Ωcm (n=33) for array B.  Preablation phase shifts were -2.1±0.5° and -6.2±0.6° for 
arrays A and B, respectively.  Factorial ANOVA revealed that preablation resistivity and 
phase shift depended on the array used in the experiments (p=0.04 for resistivity, p=0.0002 
for phase), but not on lesion location or creation order. 
To check for possible effects of cardiac excitation on impedance, 10-second 
preablation recordings were obtained at two locations on a single heart in sinus rhythm.  The 
impedances were not noticeably different for the systolic segments versus diastolic segments. 
 46 
Ablation-Induced Changes to Resistivity and Phase Shift 
Resistivity increased significantly for complete lesions for both arrays (Table 1).  No 
significant change in resistivity for either noncontinuous or nontransmural lesions was 
observed using either array A or array B.  No significant change in phase shift was observed 
for any lesion type using either array (Table 2).  Factorial ANOVA did not detect any 
significant effects of electrode array, lesion location, or lesion creation order on the observed 
changes in resistivity and phase shift.  Figure 15 and Figure 16 show the differences in 
preablation and postablation resistivity and phase shift for all lesions. 
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Table 1.  Resistivity Before and After Ablation. 
Lesion Type Pre (Ωcm) Post (Ωcm) n p 
Array A     
     Complete 194±41.6 252±42.7 8 0.022 
     Noncontinuous 182±35.8 190±35.0 6 0.59 
     Nontransmural 154±51.0 188±46.0 3 0.34 
Array B     
     Complete 126±5.3 152±10.7 17 0.0007 
     Noncontinuous 146±12.6 166±15.2 12 0.052 
     Nontransmural 144±11.6 136±7.6 4 0.43 
Table 2.  Phase Shift Before and After Ablation. 
Lesion Type Pre (deg) Post (deg) n p 
Array A     
     Complete -2.0±0.9 -2.9±1.2 8 0.43 
     Noncontinuous -1.6±0.6 -1.2±0.4 6 0.49 
     Nontransmural -3.2±0.7 -3.2±0.8 3 0.96 
Array B     
     Complete -5.2±0.6 -6.1±0.7 17 0.91 
     Noncontinuous -7.4±0.9 -8.6±1.1 12 0.30 
     Nontransmural -6.8±2.8 -6.0±3.2 4 0.29 
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Figure 15.  Change in resistivity (Δρ) for complete (C), nontransmural 
(NT), and noncontinuous (NC) lesions for array A (black bars) and array 
B (gray bars).  Error bars indicate standard error of the mean.  For both 
arrays, Δρ was statistically significant for complete lesions, but not for 
noncontinuous or nontransmural lesions (*=p<0.05). 
 
Figure 16  Change in phase shift (Δφ) for complete (C), nontransmural 
(NT), and noncontinuous (NC) lesions for array A (black bars) and array 
B (gray bars).  Error bars indicate standard error of the mean.  No 
statistically significant changes in phase shift were observed for either 
array with any lesion type (C, NC, or NT). 
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Discussion 
Main Findings 
The present study demonstrated that RF ablation produced a significant increase in 
myocardial resistivity for continuous and transmural linear lesions in saline-perfused rabbit 
ventricles.  The rises in resistivity were greater for the continuous and transmural lesions than 
for noncontinuous or nontransmural lesions, indicating impedance can distinguish 
completeness of lesions.  Changes in resistivity and phase shift were independent of lesion 
location and creation order, which suggests that an individual lesion may be evaluated 
independently of other lesions. 
Increased Tissue Resistivity after Ablation 
The increase in myocardial resistivity observed in the present study may be due to 
physiological changes both within and beyond the region of acute coagulation necrosis.  
Within the acute lesion, severe damage to the plasma membranes and microvascular 
endothelium130 prevents the maintenance of normal ionic gradients and thus alters tissue 
impedance.  Severe damage to gap junctions in the region extending up to 3 mm beyond the 
acute lesion border130 increases the resistivity of the intracellular space by disrupting the cell-
to-cell conduction pathways. 
Effects secondary to RF ablation, such as local ischemia, may also contribute to the 
observed changes in resistivity.  Damage to the microvasculature has been shown to reduce 
blood flow by 48% in the region extending up to 3 mm beyond the border of the acute 
pathological lesion in canine ventricle.131  Acute ischemia has been correlated with a 
triphasic increase in myocardial resistivity.132, 133  Effects of ischemia, including depletion of 
ATP, decreased pH, and increased intracellular calcium concentration, cause gap junction 
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resistance to increase.134-136  Intracellular calcium overload caused by hyperthermic injury at 
temperatures above 50°C137 may also contribute to increased gap junction resistance. 
Role of Lesion Completeness 
The change in resistivity detected by the four-electrode measurement likely depends 
on the volume of ablated tissue within the ellipsoid-shaped field of tissue interrogated by the 
array.179  For lesions that are both transmural and continuous, the interrogated region may 
consist primarily of ablated tissue, which would produce the greatest change in the measured 
value.  When the interrogated region includes viable tissue, such as in a noncontinuous or 
nontransmural lesion, the decreased volume of ablated tissue would produce a smaller 
change in resistivity.  This effect may account for the ability to distinguish completeness of 
the lesions. 
Role of the RF Electrode 
The stainless steel RF coil electrode (Figure 13) was present for impedance 
measurements taken with array B, but was absent for measurements taken with array A.  The 
presence of the RF coil may act as a parallel conductive pathway near the central portion of 
the lesion during impedance measurements, which can explain the 26% lower resistivity 
found with array B.  Both arrays, however, showed increased resistivity after ablation for 
complete lesions but not for noncontinuous or nontransmural lesions.  Because the resistance 
of the coil is constant, the increased resistivity after ablation was due to an increase in tissue 
resistivity.  Lesion completeness can therefore be detected even with the RF coil present. 
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Implications for Clinical Ablation 
Ideally, an RF ablation lesion set should terminate AF while preserving maximal 
atrial transport function.90, 102  Whether the aim of an RF ablation procedure for AF is to 
isolate ectopic focal triggers or to modify the maintaining substrate, the creation of 
continuous and transmural lesions is considered vital to the long-term success of the 
procedure.103, 106, 107  In fact, incomplete lesions can have a proarrhythmic effect.106, 107  
Inability to accurately detect lesion completeness also exposes patients to the risks of either 
overtreatment or undertreatment.  Undertreatment can necessitate repeat ablation procedures, 
which increases both risk of complications from surgical or catheter-based procedures and 
the expense of additional procedures.  Overtreatment, on the other hand, can result in 
unnecessary loss of atrial function and can lead to potentially life-threatening complications 
such as atrio-esophageal fistula or pericardial tamponade. 
Tests for inducibility or noninducibility of AF are provocative maneuvers that can 
cause can cause paroxysmal AF to progress to persistent AF.108  Although some investigators 
have reported improved outcomes for ablation procedures guided by inducibility tests109, 121, 
the long-term predictive value of these tests is questionable.122  Furthermore, as is the case 
with any cardiac surgery, the ablation procedure itself can promote a temporary 
proarrhythmic state123-125, which has been implicated as a possible mechanism for initial 
failure of the Cox-maze procedure.127, 128 
Tests for conduction block across lesion lines can be hampered by the occurrence of 
delayed conduction loss.111, 112  Because lesions may take days or even weeks to develop into 
mature non-conductive scar129, lesions that may ultimately provide complete block can 
appear initially unsuccessful, leading to possible overtreatment.  Pacing-based measures of 
lesion completeness, even those guided by electro-anatomical mapping, also have limitations 
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that preclude their use in certain patient populations.  For example, pacing methods are not 
possible in patients with chronic AF who are unresponsive to cardioversion 105 or in patients 
undergoing ablation concomitant with procedures requiring cardioplegia.  Although other 
ablation endpoints such as reduction of electrogram amplitude and increase of pacing 
threshold are sometimes used, these have limited ability to predict long-term procedural 
outcomes.107 
The present study demonstrated that myocardial electrical impedance measured with 
the four-electrode method can indicate lesion completeness.  This method may provide an 
alternative or additional metric of lesion completeness that can overcome certain limitations 
of current ablation endpoints.  Since impedance is a passive tissue property and does not 
require pacing, it could potentially be used to evaluate lesion quality in a larger patient 
population than pacing-based endpoints.  Impedance may also provide a direct measure of 
the degree of injury to ablated tissue independent of transient loss of excitability or 
conduction. 
Study Limitations 
Possible effects of ablation on blood cells may affect resistivity.  However, tissue 
contributes more than blood to the resistivity of myocardium.159  Resistivity in rabbit 
ventricles may differ from that in human atria due to possible interspecies or atrioventricular 
tissue differences.  However, resistivity increased with ablation at different locations on the 
hearts, indicating applicability is not limited to a particular location.  In addition, since 
effects of ablation are due to heat and not tissue-specific membrane properties, the effects 
may occur in other tissues. 
 
  
CHAPTER 5 
DIAGNOSTIC ACCURACY OF RESISTIVITY AND STIMULUS-EXCITATION DELAY 
AS METRICS OF LESION COMPLETENESS IN ISOLATED RABBIT HEARTS 
Introduction 
Myocardial impedance may provide an alternative measure of lesion completeness for 
RF ablation procedures.  In Chapter 4, it was shown that myocardial resistivity, on average, 
increases more for complete lesions than for incomplete lesions.  This aggregate difference, 
however, does not indicate the ability of resistivity as a diagnostic test to the completeness of 
individual lesions.  When a continuous variable, such as resistivity or stimulus-excitation 
delay, is used for binary classification (e.g. complete or incomplete), it is necessary to 
determine the threshold level that provides the most accurate discrimination between the two 
possible outcomes.  This threshold value is often determined using receiver operating 
characteristic (ROC) analysis.180-183  In this chapter, ROC analysis is used to determine the 
diagnostic accuracy of both resistivity and translesion stimulus-excitation delay to predict 
lesion completeness as identified by pathological examination. 
ROC analysis evaluates the sensitivity and specificity of a diagnostic test over a range 
of threshold values.  For a given threshold, the sensitivity is the proportion of positive results 
to the actual number of positives (e.g. the number of true positives and false negatives); the 
specificity is the proportion of true negative results identified to the number of actual 
negatives (e.g. the number of all true negatives and false positives).184, 185  The number of 
actual positives and negatives may be determined from a gold standard measurement, such as 
pathological examination.180, 181, 184  Determination of the optimal threshold value depends 
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upon the relative importance of its sensitivity and specificity.183  If the sensitivity and 
specificity of the test are equally important, then the optimal threshold is the one at which the 
sum of sensitivity and specificity is maximized.180, 181 
Methods 
Tissue Preparation 
Hearts from New Zealand White rabbits (n=21) were isolated in accordance with a 
protocol approved by the Institutional Animal Care and Use Committee of the University of 
North Carolina at Chapel Hill.  Rabbits were euthanized by aural IV injection of a solution of 
sodium pentobarbital (120 mg/kg) and heparin (1000 USP units).  Following injection, the 
level of anesthesia was verified by toe pinch and the heart was excised.  The heart was 
quickly washed in Tyrode’s solution containing 129 mM NaCl, 5.4 mM KCl, 1.8 mM 
CaCl2•2H2O, 1.1 mM MgCl2•6H2O, 26 mM NaHCO3, 1.0 mM Na2HPO4•H2O, 11 mM D-
(+)-Glucose, and 0.606 μM Bovine Serum Albumin (A7030, Sigma-Aldrich, St. Louis, MO).  
The aorta was then cannulated on a Langendorff perfusion apparatus and perfused with 
Tyrode’s solution at a rate of 30 mL/min at 37.0±0.5°C.  The perfusate was bubbled with a 
mixture of 95% O2 and 5% CO2. 
Lesion Creation 
Lesions (n=57) were created using a 2-cm linear RF coagulation device (CS-1002, 
nContact Surgical) and a 480 kHz RF generator (800XP EPT-1000 XP, EP Technologies, 
Sunnyvale CA).  The unipolar RF electrode, shown in Figure 13 (Chapter 4), was held in 
place by suction (-400 mmHg) and was referenced to an RF return electrode (area 15 cm2) 
that cradled the opposing side of the heart. 
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Lesions were located on the left ventricular free wall (LV), posterior septum (PS), or 
anterior septum (AS).  Two collinear applications of RF (15-20W, 15-30sec) aligned end to 
end were used to create each lesion.  Continuous lesions were created by slightly overlapping 
the two applications, while noncontinuous lesions were created by leaving space between the 
two applications.  Transmural and nontransmural lesions were achieved by adjusting the RF 
power and duration within the ranges specified above.  All lesions extended from the atrio-
ventricular groove to the ventricular apex, with the exception of gaps in noncontinuous 
lesions. 
Myocardial Impedance and Stimulus-Excitation Delay 
As described in Chapter 4, myocardial impedance was measured before and after 
ablation for 50 lesions (18 hearts).  Stimulus-excitation delay was measured for 23 lesions, of 
which 16 were from the original 18 hearts and 7 were from an additional 3 hearts.  The same 
four-electrode arrays were used for both impedance and stimulus-excitation delay 
measurements.  The methods and instrumentation used for stimulus-excitation delay 
measurements are described by Himel et al.186  Briefly, electrodes E1 and E2 were used to 
deliver pacing stimuli on one side of the lesion and electrodes E3 and E4 were used to 
measure the bipolar electrogram on the other side.  Pacing stimulus pulses with 3-4 ms 
duration were delivered at 360-660 ms intervals using a stimulus isolator (Isostim A320, 
World Precision Instruments, Sarasota, FL).  Stimulus amplitude was set to 2x pacing 
threshold (maximum 10 mA).  The pacing stimulus and bipolar electrogram were recorded at 
a sample rate of 10 kHz per channel for 10 seconds using the acquisition system described in 
Chapter 3 and Chapter 4.  For measurements of both impedance and stimulus-excitation 
delay, the electrode array was oriented perpendicular to the apicobasal axis and placed 
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midway between the atrioventricular groove and the ventricular apex.  Stimulation-excitation 
delay recordings were taken 10±1.1 minutes before and 13±1.4 minutes after application of 
RF.  Stimulus-excitation delay was defined as the time from the onset of the pacing stimulus 
to the time of maximum deflection of the bipolar electrogram.187 
Examination of Lesions 
At the conclusion of each experiment, the heart was stained with a solution of 2,3,5-
triphenyltetrazolium chloride (TTC, Sigma-Aldrich; 2.1g TTC in 150mL normal saline) 
delivered by arterial perfusion.  The TTC demarcated lesion boundaries by staining viable 
tissue dark red.  Lesions were then bisected longitudinally and classified according to 
continuity and transmurality (Figure 14, Chapter 4).  Complete lesions had no viable tissue 
between the endocardium and epicardium over any part of the lesion length.  Noncontinuous 
lesions had a viable gap extending from endocardium to epicardium.  Nontransmural lesions 
had a viable region between the lesion and the endocardium that spanned the entire lesion 
length. 
Statistical Analysis 
The receiver operating characteristic curve was calculated for the change in resistivity 
(∆ρ) and for the change in stimulus-excitation delay (∆SED) resulting from RF ablation.  The 
gold standard measure of actual outcomes was determined from pathological examination of 
lesions stained with TTC.  Complete lesions were classified as positives and lesions that were 
either noncontinuous or nontransmural were classified as negatives.  Sensitivity and 
specificity for ∆ρ and ∆SED were calculated for threshold values ranging from -30 to 130 
Ωcm in increments of 1 Ωcm for ∆ρ and from -40 ms to 130 ms in increments of 1 ms for 
∆SED.  These range limits were chosen because they included the full range of ∆ρ and ∆SED 
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values that were observed in experiments.  At each of the threshold values for ∆ρ and ∆SED, 
sensitivity was calculated by Equation 11 and specificity was calculated by Equation 12: 
 ܵ݁݊ݏ݅ݐ݅ݒ݅ݐݕ ൌ
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where NTP is the number of true positives, NFN is the number of false negatives, NTN is the 
number of true negatives, and NTN is the number of false positives.180, 184  The optimal 
threshold values for ∆ρ and ∆SED were calculated by finding the threshold that maximized 
the value of Youden’s index (J, Equation 13).181 
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Results 
Receiver operating characteristic curve 
Figure 17 shows the receiver operating characteristic curves for ∆ρ and ∆SED.  The 
optimal threshold value for ∆ρ was 19 Ωcm, at which sensitivity was 0.60 (CI95%: 0.41 to 
0.79) and specificity was 0.76 (CI95%: 0.59 to 0.92).  The optimal threshold value for ∆SED 
was 30 ms, at which sensitivity was 1.00 (CI95%: 1.00 to 1.00) and specificity was 0.69 
(CI95%: 0.44 to 0.94).  Qualitatively, this plot shows that stimulus-excitation delay is more 
accurate than resistivity as a diagnostic indicator of lesion completeness.  It is worth noting 
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that each ROC curve lies within the 95% confidence interval of the other curve over a 
majority of the threshold range. 
 
Figure 17.  Receiver operating characteristic curves for changes in 
resistivity (∆ρ) and stimulus-excitation delay (∆SED).  The data points 
corresponding to the optimal threshold value for each metric are 
indicated by red circles. 
In 16 lesions, both ∆ρ and ∆SED were measured.  Figure 18 shows the relationship 
between ∆ρ and ∆SED for those lesions and the optimal threshold for each (dotted lines).  
For these 16 lesions, 8 were complete and 8 were incomplete.  Using the 19 Ωcm threshold, 
∆ρ correctly identified 7 incomplete lesions and 7 complete lesions (sensitivity = 0.875, 
specificity = 0.875).  At the 30 ms threshold level, ∆SED correctly identified 5 incomplete 
lesions and all 8 complete lesions (sensitivity = 1.00, specificity = 0.625). 
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Figure 18.  Comparison of change in impedance (∆ρ) to change in 
stimulus excitation delay (∆SED) for lesions in which both measurements 
were taken.  Dotted horizontal and vertical lines indicate optimal 
threshold values for ∆ρ and ∆SED, respectively.  The labels located 
slightly above and to the left of data points for noncontinuous lesions (red 
dots) indicate width of the viable gap (mm). 
Discussion 
Receiver operating characteristic (ROC) analysis was used to assess the diagnostic 
accuracy of changes in myocardial resistivity (∆ρ) and stimulus-excitation delay (∆SED) for 
prediction of RF lesion completeness in isolated rabbit hearts.  At the optimal threshold 
values (19 Ωcm for ∆ρ and 30 ms for ∆SED), ∆SED showed higher sensitivity (1.0 vs 0.60), 
but ∆ρ showed higher specificity (0.76 vs 0.69). The proportion of incomplete lesions 
incorrectly identified as complete (false positives) was higher for ∆SED than for ∆ρ.  The 
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proportion of complete lesions incorrectly classified as incomplete (false negatives), 
however, was higher for ∆ρ than for ∆SED. 
This study demonstrated proof-of-concept for the use of myocardial resistivity as a 
metric of lesion completeness for RF ablation.  Comparison of ∆ρ to ∆SED indicated that ∆ρ 
has greater specificity while ∆SED has greater sensitivity.  It is therefore plausible that a 
combination of ∆ρ and ∆SED provides a better metric of lesion completeness than either one 
would provide alone.  For use in a clinical setting, it will be necessary to reevaluate the 
optimal threshold value for ∆ρ in human atria. 
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APPENDIX 1:  EFFECT OF ELECTRODE SIZE ON DISTRIBUTION OF 
POTENTIAL FOR FOUR-ELECTRODE IMPEDANCE MEASUREMENTS 
Introduction 
The underlying theory of the four-electrode method assumes that the array is 
composed of infinitesimally small point electrodes.  This assumption of point electrodes may 
be valid if the size of the electrodes is small relative to the interelectrode spacing.  For most 
practical applications of the four-electrode method in biologic tissue, however, the electrodes 
do have a finite size.  In these cases, the assumption of point electrodes may not be valid.  
The following discussion examines the effect of electrode size on impedance measurements 
for a four-electrode array with disk-shaped electrodes for current delivery (E1 and E4) and 
point electrodes for voltage measurement (E2 and E3). 
Impedance Equations for Disk-Shaped Electrodes 
When current is applied to a volume conductor, the resulting potential gradient is 
determined by properties of the conductor itself and of the electrodes.  If current is applied 
through two point electrodes located on the surface of a semi-infinite volume conductor that 
is homogeneous, isotropic, purely resistive, and bounded on one side by an insulating 
medium, then the potential gradient can be described by a rather simple formula (Equation 
14): 
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where Vx,y,z is the voltage at point (x,y,z), ρ is the resistivity of the volume conductor, IA is the 
applied current, and d1 and d2 are the distances, respectively, to each of the two electrodes.150  
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If, instead of point electrodes, the current is delivered via circular disk electrodes, the 
expression for the potential field then becomes (Equation 15): 
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where r is the electrode radius.161 
Consider a linear four-electrode array that is located on the surface of the ideal 
volume conductor.  The array has interelectrode distances: a from E1 to E2, b from E2 to E3, 
and c from E3 to E4.  If the current is delivered by disk electrodes (E1 and E4, radius = r), 
but voltage is measured by point electrodes (E2 and E3), then the voltages at E2 and E3, 
respectively, are expressed by Equation 16 and Equation 17: 
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By superposition, an expression is found for the difference in voltage between E2 and 
E3 (∆VE2,E3,Equation 18): 
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Separating the constants and rearranging yields an expression for ρ (Equation 19), 
which contains the scalar constant K (Equation 20): 
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Equation 20 
When the distance from E1 and E2 is equal to the distance from E3 to E4, the 
equation for K simplifies to (Equation 21): 
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 Equation 21 
When the electrodes are equally spaced, the equation for K simplifies to (Equation 
22): 
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Illustrative Example 
The following example examines the effect of electrode size on the distribution of 
potential in an isotropic, homogeneous, semi-infinite medium with resistivity of 200 Ωcm 
and the effect of that potential distribution on the impedance measured with a four-electrode 
array.  In this example, circular disk electrodes are used for current delivery (E1 and E4) and 
point electrodes are used for voltage-measurement (E2 and E3).  The effect of disk radius is 
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examined for three different four-electrode arrays with varying interelectrode spacing.  Array 
1 has interelectrode distances of 1.7 mm (E1-E2 and E3-E4) and 14 mm (E2-E3), similar to 
the electrode arrays used for rabbit experiments (Chapter 4).  Array 2 has interelectrode 
distances of 1 mm (E1-E2 and E3-E4) and 4 mm (E2-E3).  For Array 3, the distance between 
all electrodes is 2 mm. 
For Array 1, the potential distributions are shown for three different radii for E1 and 
E4.  Figure 19 shows the potential distribution for the limiting case, in which the radius is 0 
mm (point electrodes).  Potential distributions for electrode radii of 0.5 mm and 1.0 mm are 
shown in Figure 20 and Figure 21, respectively.  Even though the 0.5 mm radius covers 30% 
of the interelectrode distance (1.7 mm), the potential distribution is qualitatively similar to 
that produced by the point electrodes.  When the electrode radius is increased to 1 mm, or 
60% of the interelectrode distance, the potential distribution differs markedly from the 
distribution produced by the point electrodes.  From the potential distributions for radii of 0.5 
mm and 1.0 mm, it is evident that the assumption of point electrodes may hold if the 
electrode size is small relative to the interelectrode spacing. 
Figure 22 shows the effect of electrode size on the apparent measured resistivity (ρ) 
for all three arrays when the calibration constant (K) is calculated based on the assumption of 
point electrodes.  As shown in the figure, the apparent resistivity increases with increasing 
electrode radius.  For all three arrays, the apparent resistivity is within 2% of the actual 
resistivity for electrode radii smaller than 25% of the distance between the current-delivery 
and voltage measurement electrodes.  Correspondingly, the actual value of K decreases with 
increasing electrode radius as shown in Figure 23. 
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Figure 19.  Potential distribution resulting from a 10μA current applied 
via point electrodes E1 and E4 to the surface of a homogeneous, isotropic, 
semi-infinite medium with ρ=200 Ωcm.  E2 and E3 are the voltage 
measurement electrodes in the four-electrode array.  Interelectrode 
distances a and b are 1.7mm and 14mm, respectively.  Top panel shows 
the 3-dimensional potential distribution.  Middle panel shows a 2-
dimensional slice along the electrode array axis.  Bottom panel shows the 
potential along the electrode array axis at the surface of the medium. 
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\  
Figure 20.  Potential distribution resulting from a 10μA bipolar current 
applied via circular disk electrodes E1 and E4 (radius = 0.50mm) to the 
surface of a homogeneous, isotropic, semi-infinite medium with ρ=200 
Ωcm.  E2 and E3 are the voltage measurement electrodes in the four-
electrode array.  Interelectrode distances a and b are 1.7mm and 14mm, 
respectively.  Top panel shows the 3-dimensional potential distribution.  
Middle panel shows a 2-dimensional slice along the electrode array axis.  
Bottom panel shows the potential along the electrode array axis at the 
surface. 
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Figure 21.  Potential distribution resulting from a 10μA bipolar current 
applied via circular disk electrodes E1 and E4 (radius = 1.00mm) to the 
surface of a homogeneous, isotropic, semi-infinite medium with ρ=200 
Ωcm.  E2 and E3 are the voltage measurement electrodes in the four-
electrode array.  Interelectrode distances a and b are 1.7mm and 14mm, 
respectively.  Top panel shows the 3-dimensional potential distribution.  
Middle panel shows a 2-dimensional slice along the electrode array axis.  
Bottom panel shows the potential along the electrode array axis at the 
surface. 
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Figure 22.  Effect of electrode radius on measured resistivity (ρ) for three 
different arrays when calibration constant (K) assumes point electrodes.  
Electrode radii are expressed as a percentage of interelectrode distance 
between the current-delivery and voltage-measurement electrodes. 
 
Figure 23.  Effect of electrode radius on calibration constant (K) for three 
arrays compared to K calculated using assumption of point electrodes.  
Electrode radii are expressed as a percentage of interelectrode distance 
between the current-delivery and voltage-measurement electrodes. 
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APPENDIX 2: MATLAB CODE FOR ANALYSIS OF IMPEDANCE AND 
STIMULUS-EXCITATION DELAY MEASUREMENTS 
%******************************************************************************************** 
% RCV_Reader.m 
% 
%-------------------------------------------------------------------------------------------- 
% VERSION HISTORY: 
% 
%******************************************************************************************** 
 
clear all; 
close all; 
format compact; 
 
%============================================================================================ 
% Read File 
%-------------------------------------------------------------------------------------------- 
 
filelist=input('Please select filelist','s'); 
st=strcat(cd,'\',filelist,'csv'); 
fid=fopen(st,'r'); 
 
i=0; 
while feof(fid)~=1 
    i=i+1; 
    filename{i}=fgetl(fid); 
end 
fclose(fid); 
filename' 
 
%Open File 
f=input('Input file number:  '); 
st=strcat(cd,'\Electrical Recording Data Files\',filename{f}); 
fid=fopen(st,'r'); 
 
tic; 
 
%First 4 bytes = length of binary header remaining 
a=fread(fid,4,'uchar'); 
hdrsize=a(1)*16^8+a(2)*16^4+a(3)*16^2+a(4); 
 
%Second 4 bytes = length of channel list 
a=fread(fid,4,'uchar'); 
chanlistsize=a(1)*16^8+a(2)*16^4+a(3)*16^2+a(4); 
 
%Get Channel List 
chanlist=fscanf(fid,'%c',chanlistsize); 
 
%Get Channel Info List Length 
a=fread(fid,4,'uchar'); 
infolistsize=a(1)*16^8+a(2)*16^4+a(3)*16^2+a(4); 
 
%Get Number of Channels 
a=fread(fid,4,'uchar'); 
numchans=a(1)*16^8+a(2)*16^4+a(3)*16^2+a(4); 
 
%_____________________________________________________________________________________% 
 
for i=1:numchans 
     
    %Get Individual Channel Number String Length 
    a=fread(fid,4,'uchar'); 
    channumstrsize(i)=a(1)*16^8+a(2)*16^4+a(3)*16^2+a(4); 
    %channumstrsize=a(1)*16^8+a(2)*16^4+a(3)*16^2+a(4) 
     
    %---------------------------------------------------------------------------------% 
     
    %Get Channel Number 
    channum(i)=str2num(fscanf(fid,'%c',channumstrsize(i))); 
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    %channum=str2num(fscanf(fid,'%c',channumstrsize)) 
     
    %---------------------------------------------------------------------------------% 
     
    %Get High Input Limit (SGL) 
    a=fread(fid,4); 
    b=strcat(dec2bin(a(1),8),dec2bin(a(2),8),dec2bin(a(3),8),dec2bin(a(4),8)); 
    if bin2dec(b(1))==0 
        sign=1; 
    else 
        sign=-1; 
    end 
    exp=bin2dec(b(2:9))-127; 
    frac=b(10:32); 
    x=1; 
    for k=1:23 
        x=x+(bin2dec(frac(k)))/(2^k); 
    end 
    highlimit(i)=sign*2^exp*x; 
    %highlimit=sign*2^exp*x 
     
    %---------------------------------------------------------------------------------% 
     
    %Get Low Input Limit (SGL) 
    a=fread(fid,4); 
    b=strcat(dec2bin(a(1),8),dec2bin(a(2),8),dec2bin(a(3),8),dec2bin(a(4),8)); 
    if bin2dec(b(1))==0 
        sign=1; 
    else 
        sign=-1; 
    end 
    exp=bin2dec(b(2:9))-127; 
    frac=b(10:32); 
    x=1; 
    for k=1:23 
        x=x+(bin2dec(frac(k)))/(2^k); 
    end 
    lowlimit(i)=sign*2^exp*x; 
    %lowlimit=sign*2^exp*x 
     
    %---------------------------------------------------------------------------------% 
     
    %Get Range (SGL) 
    a=fread(fid,4); 
    b=strcat(dec2bin(a(1),8),dec2bin(a(2),8),dec2bin(a(3),8),dec2bin(a(4),8)); 
    if bin2dec(b(1))==0 
        sign=1; 
    else 
        sign=-1; 
    end 
    exp=bin2dec(b(2:9))-127; 
    frac=b(10:32); 
    x=1; 
    for k=1:23 
        x=x+(bin2dec(frac(k)))/(2^k); 
    end 
    range(i)=sign*2^exp*x; 
    %range=sign*2^exp*x 
     
    %---------------------------------------------------------------------------------% 
     
    %Get Polarity (U16) (0='no change', 1='bipolar', 2='unipolar') 
    a=fread(fid,2,'uchar'); 
    polarity(i)=a(1)*16^2+a(2); 
    %polarity=a(1)*16^2+a(2) 
     
    %---------------------------------------------------------------------------------% 
     
    %Get Gain (SGL) 
    a=fread(fid,4); 
    b=strcat(dec2bin(a(1),8),dec2bin(a(2),8),dec2bin(a(3),8),dec2bin(a(4),8)); 
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    if bin2dec(b(1))==0 
        sign=1; 
    else 
        sign=-1; 
    end 
    exp=bin2dec(b(2:9))-127; 
    frac=b(10:32); 
    x=1; 
    for k=1:23 
        x=x+(bin2dec(frac(k)))/(2^k); 
    end 
    gain(i)=sign*2^exp*x; 
    %gain=sign*2^exp*x 
     
    %---------------------------------------------------------------------------------% 
     
    %Get Coupling (U16) (0='no change', 1='DC', 2='AC', 3='ground', 4='internal reference') 
    a=fread(fid,2,'uchar'); 
    coupling(i)=a(1)*16^2+a(2); 
    %coupling=a(1)*16^2+a(2) 
     
    %---------------------------------------------------------------------------------% 
     
    %Get Input Mode (U16) (0='no change', 1='differential', 2='rse', 3='nrse') 
    a=fread(fid,2,'uchar'); 
    inputmode(i)=a(1)*16^2+a(2); 
    %inputmode=a(1)*16^2+a(2) 
     
    %---------------------------------------------------------------------------------% 
     
    %Get Scale Multiplier (SGL) 
    a=fread(fid,4); 
    b=strcat(dec2bin(a(1),8),dec2bin(a(2),8),dec2bin(a(3),8),dec2bin(a(4),8)); 
    if bin2dec(b(1))==0 
        sign=1; 
    else 
        sign=-1; 
    end 
    exp=bin2dec(b(2:9))-127; 
    frac=b(10:32); 
    x=1; 
    for k=1:23 
        x=x+(bin2dec(frac(k)))/(2^k); 
    end 
    scalemultiplier(i)=sign*2^exp*x; 
    %scalemultiplier=sign*2^exp*x 
     
    %---------------------------------------------------------------------------------% 
     
    %Get Scale Offset (SGL) 
    a=fread(fid,4); 
    b=strcat(dec2bin(a(1),8),dec2bin(a(2),8),dec2bin(a(3),8),dec2bin(a(4),8)); 
    if bin2dec(b(1))==0 
        sign=1; 
    else 
        sign=-1; 
    end 
    exp=bin2dec(b(2:9))-127; 
    frac=b(10:32); 
    x=1; 
    for k=1:23 
        x=x+(bin2dec(frac(k)))/(2^k); 
    end 
    scaleoffset(i)=sign*2^exp*x; 
    %scaleoffset=sign*2^exp*x 
     
    %---------------------------------------------------------------------------------%  
end 
 
%_____________________________________________________________________________________% 
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%Get Scan Rate (SGL) 
a=fread(fid,4); 
b=strcat(dec2bin(a(1),8),dec2bin(a(2),8),dec2bin(a(3),8),dec2bin(a(4),8)); 
if bin2dec(b(1))==0 
    sign=1; 
else 
    sign=-1; 
end 
exp=bin2dec(b(2:9))-127; 
frac=b(10:32); 
x=1; 
for k=1:23 
    x=x+(bin2dec(frac(k)))/(2^k); 
end 
scanrate=sign*2^exp*x; 
 
%---------------------------------------------------------------------------------%  
 
%Get Remainder of Header (variable length) 
%(Contains test date, test time, and user supplied header) 
remain=hdrsize+4-ftell(fid); 
a=fscanf(fid,'%c',remain); 
[WindowLength,a]=strtok(a,9); 
[testdate,a]=strtok(a,9); 
[testtime,userheader]=strtok(a,9); 
 
%_____________________________________________________________________________________% 
%_____________________________________________________________________________________% 
 
%Get Data 
fseek(fid,hdrsize+4,'bof'); 
 
%Get File Length 
linecount=0; 
while feof(fid)==0 
    a=fread(fid,numchans*2); 
    linecount=linecount+1; 
end 
linecount=linecount-1; 
 
%Return to beginning of data 
fseek(fid,hdrsize+4,'bof'); 
 
%Read Unscaled Data to Array 
binary_data=fread(fid,2*linecount*numchans); 
binary_data=reshape(binary_data,2,length(binary_data)/2); 
H_Byte=binary_data(1,:); 
L_Byte=binary_data(2,:); 
x=H_Byte>127; 
x=x*2^16; 
data=H_Byte*256+L_Byte-x; 
data=reshape(data,numchans,length(data)/numchans); 
clear binary_data H_Byte L_Byte x 
 
%Scale Multiplier and Offset 
for i=1:numchans 
    data(i,:)=data(i,:)*scalemultiplier(i)+scaleoffset(i); 
end 
 
%Create Time Array 
time=0:1:(length(data(1,:))-1); 
time=time./scanrate; 
 
%Close File 
fclose(fid); 
 
%Clear Unused Variables 
clear a b i k chanlist chanlistsize channum channumstrsize coupling exp fid filelist  
clear frac gain hdrsize highlimit infolistsize inputmode linecount lowlimit numchans 
clear polarity range remain scalemultiplier scaleoffset sign st WindowLength  
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%_____________________________________________________________________________________% 
%_____________________________________________________________________________________% 
 
%============================================================================================ 
% ANALYZE FILE DATA 
%-------------------------------------------------------------------------------------------- 
 
 
%=================================================== 
% FIND MODE (RESISTIVITY OR CONDUCTION VEL.) 
%=================================================== 
if isempty(findstr(filename{f},'R4E'))==0 
    MeasMode='R4E'; 
    R_Sense=991; 
    R_Calib_Offset=input('Offset:  '); %77.34 
elseif isempty(findstr(filename{f},'R2E'))==0 
    MeasMode='R2E'; 
    R_Sense=991; 
    R_Calib_Offset=0 
elseif isempty(findstr(filename{f},'CV'))==0 
    MeasMode='CV'; 
    R_Sense=10.2; 
end 
 
Gain_I=100; 
Gain_V=97.69; 
Gain_E2=100; 
Gain_E4=100; 
 
 
%=================================================== 
% RESISTIVITY 
%=================================================== 
if strcmp(MeasMode(1),'R') 
     
    %---------------------------------------------- 
    % Calibrate Ih and Vh 
    %---------------------------------------------- 
    Ih=data(1,:)/Gain_I/R_Sense; 
    Ih=Ih-mean(Ih); 
    Vh=data(2,:)/Gain_V; 
    Vh=Vh-mean(Vh); 
     
    %---------------------------------------------- 
    % Find Find R by Peak-to-Peak and RMS in 1 ms windows 
    %---------------------------------------------- 
    n=1000*(length(Ih)/scanrate)-1 
    for i=1:n 
        if i==1 
            ind(1)=1; 
            ind(2)=i*scanrate/1000+1; 
        else 
            ind(1)=(i-1)*scanrate/1000+1; 
            ind(2)=i*scanrate/1000+1; 
        end 
         
        Ih_PP(i)=max(Ih(ind(1):ind(2)))-min(Ih(ind(1):ind(2))); 
        Vh_PP(i)=max(Vh(ind(1):ind(2)))-min(Vh(ind(1):ind(2))); 
        R_PP(i)=Vh_PP(i)/Ih_PP(i)-R_Calib_Offset; 
           
        Vh_RMS(i)=sqrt(sum((Vh(ind(1):ind(2))-... 
            mean(Vh(ind(1):ind(2)))).^2)/length(Vh(ind(1):ind(2))));  
        Ih_RMS(i)=sqrt(sum((Ih(ind(1):ind(2))- ... 
            mean(Ih(ind(1):ind(2)))).^2)/length(Ih(ind(1):ind(2))));  
        R_RMS(i)=Vh_RMS(i)/Ih_RMS(i)-R_Calib_Offset; 
    end 
     
    %---------------------------------------------- 
    % Find R by FFT 
    %---------------------------------------------- 
 74 
    p=20 
    Y1 = fft(Ih,2^p); 
    Y2 = fft(Vh,2^p); 
     
    Pyy1 = Y1.* conj(Y1) / 2^p;   
    Pyy1=Pyy1(1:(1+2^(p-1))); 
    Pyy2 = Y2.* conj(Y2) / 2^p;   
    Pyy2=Pyy2(1:(1+2^(p-1))); 
     
    PhShift=angle(Y2)-angle(Y1); 
    PhShift=PhShift(1:(1+2^(p-1))); 
     
    Freq = scanrate*(0:(2^(p-1)))/(2^p); 
 
    f1=Freq>1000-100;  
    f2=Freq<1000+100;  
    f3=and(f1,f2);  
    F_Index=find(f3');  
    F_Index=round(mean(F_Index)); 
    clear f1 f2 f3; 
 
    % Integrate FFT over interval centered on 1kHz 
    int_width_Hz=40 
    f1=Freq>1000-int_width_Hz/2;  
    f2=Freq<1000+int_width_Hz/2;  
    f3=and(f1,f2); 
    f3=find(f3'); 
    Int_Index=[min(f3) max(f3)]; 
    clear f1 f2 f3 
     
    Freq_FFT=Freq(Int_Index(1):Int_Index(2));     
    Ih_FFT=sqrt(sum(Pyy1(Int_Index(1):Int_Index(2)))); 
    Vh_FFT=sqrt(sum(Pyy2(Int_Index(1):Int_Index(2)))); 
    R_FFT=Vh_FFT/Ih_FFT-R_Calib_Offset; 
     
    for j = 1:(length(Ih)/200)-1; 
        searchstart1 = ((j-1)*200)+1; 
        searchend1 = j*200; 
        [wave1max,time1]=max(Ih(searchstart1:searchend1)); 
        time1 = time1 + searchstart1; 
        searchstart2 = time1; 
        searchend2 = time1 + 199; 
        [wave2max,time2]=max(Vh(searchstart2:searchend2)); 
        time2 = time2 + searchstart2; 
        phaselag(j) = (time2-time1)/200; 
    end; 
     
    phaselag2=mean(phaselag)*360 
     
    Freq(F_Index) 
    PhShift=-PhShift(F_Index)*180/pi 
     
     
     
    %---------------------------------------------- 
    % Plot Ih, Vh, R(P-P), R(RMS), and FFT 
    %---------------------------------------------- 
    figure(1); 
    LabelFontSize=8; 
    YLabel_X_Pos=-0.07; 
     
    % PLOT IH 
    subplot(4,2,[1:2]) 
    plot(time,(Ih-mean(Ih))*1E6) 
    title(strrep(strcat(filename{f},'________',testtime),'_',' ')) 
    xlabel('Time (s)','FontSize',LabelFontSize) 
    ylabel('I_h (\muA)','Units','Normalized','VerticalAlignment','top') 
    pos=get(get(gca,'YLabel'),'Position'); 
    pos(1)=YLabel_X_Pos; 
    set(get(gca,'YLabel'),'Position',pos); 
    set(gca,'FontSize',LabelFontSize) 
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    % PLOT VH 
    subplot(4,2,[3:4]) 
    plot(time,(Vh-mean(Vh))*1E3) 
    xlabel('Time (s)','FontSize',LabelFontSize) 
    ylabel('V_h (mV)','Units','Normalized','VerticalAlignment','top') 
    pos=get(get(gca,'YLabel'),'Position'); 
    pos(1)=YLabel_X_Pos; 
    set(get(gca,'YLabel'),'Position',pos); 
    set(gca,'FontSize',LabelFontSize) 
     
    % PLOT R(P-P) and R(RMS) 
    subplot(4,2,[5:6]) 
    if n<100 
        plot([1:length(R_PP)],R_PP,'-ob',[1:length(R_RMS)],R_RMS,'-*k'); 
    else 
        plot([1:length(R_PP)],R_PP,'b',[1:length(R_RMS)],R_RMS,'k'); 
    end 
    xlim([0 n+1]); 
    minY=min(min(R_PP),min(R_RMS)); 
    maxY=max(max(R_PP),max(R_RMS)); 
    ylim([minY-0.05*(maxY-minY) maxY+0.35*(maxY-minY)]); 
    str1=strcat('R_P_-_P =',strrep(strcat('_',num2str(mean(R_PP),'%.1f')),'_',' ')); 
    str2=strrep(strcat(' \pm_',num2str(std(R_PP),'%.1f '),... 
        '\Omega (n=',num2str(length(R_PP)),')'),'_',' '); 
    str3=strcat('R_R_M_S =',strrep(strcat('_',num2str(mean(R_RMS),'%.1f')),'_',' ')); 
    str4=strrep(strcat(' \pm_',num2str(std(R_RMS),'%.1f '),... 
        '\Omega (n=',num2str(length(R_PP)),')'),'_',' '); 
    text((min(get(gca,'xlim'))+0.025*diff(get(gca,'xlim'))),... 
        (min(get(gca,'ylim'))+0.90*diff(get(gca,'ylim'))),... 
        strvcat(strcat(str1,str2),strcat(str3,str4)),... 
        'HorizontalAlignment','left','VerticalAlignment','top','FontSize',LabelFontSize) 
    xlabel('Cycle Number','FontSize',LabelFontSize) 
    ylabel('R (\Omega)','Units','Normalized','VerticalAlignment','top') 
    pos=get(get(gca,'YLabel'),'Position'); 
    pos(1)=YLabel_X_Pos; 
    set(get(gca,'YLabel'),'Position',pos); 
    set(gca,'FontSize',LabelFontSize) 
    legend('R_P_-_P','R_R_M_S') 
 
    % PLOT FFT of Ih 
    subplot(12,2,[21:2:23]) 
    plot(Freq,Pyy1) 
    xlim([0 2000]); 
    ylim([0 1.1*max(Pyy1(Int_Index(1):Int_Index(2)))]); 
    xlabel('Frequency (Hz)','FontSize',LabelFontSize) 
    ylabel('I_h Pwr','Units','Normalized','VerticalAlignment','top') 
    pos=get(get(gca,'YLabel'),'Position'); 
    pos(1)=2.2*YLabel_X_Pos; 
    set(get(gca,'YLabel'),'Position',pos); 
    set(gca,'FontSize',LabelFontSize) 
     
    % PLOT FFT of Vh 
    subplot(12,2,[22:2:24]) 
    plot(Freq,Pyy2) 
    ylim([0 1.1*max(Pyy2(Int_Index(1):Int_Index(2)))]); 
    xlim([0 2000]); 
    xlabel('Frequency (Hz)','FontSize',LabelFontSize) 
    ylabel('V_h Pwr','Units','Normalized','VerticalAlignment','top') 
    pos=get(get(gca,'YLabel'),'Position'); 
    pos(1)=2*YLabel_X_Pos; 
    set(get(gca,'YLabel'),'Position',pos);    
    set(gca,'FontSize',LabelFontSize) 
    str1=strcat('R_F_F_T =',strrep(strcat('_',num2str(R_FFT,'%.1f'),' \Omega'),'_',' ')); 
    str2=strcat('(\DeltaF_ =',num2str(int_width_Hz),'Hz)'); 
    text((min(get(gca,'xlim'))+0.65*diff(get(gca,'xlim'))),... 
        (min(get(gca,'ylim'))+0.5*diff(get(gca,'ylim'))),... 
        strvcat(str1,' ',str2),... 
        'HorizontalAlignment','left','VerticalAlignment','middle','FontSize',LabelFontSize) 
     
    %---------------------------------------------- 
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    % Write to File? 
    %---------------------------------------------- 
    write_to_file=input('Write to File? (Y/N): ','s'); 
    if strcmp(lower(write_to_file),'y')==1 
        write_to_file=1; 
    else 
        write_to_file=0; 
    end 
 
    %---------------------------------------------- 
    % Save Data and Plot to To File 
    %---------------------------------------------- 
 
    if write_to_file==1 
        %---------------------------------------------- 
        % Write to File 
        %---------------------------------------------- 
         
        if exist('Data Summary - Resistivity.txt')==0 
            fid=fopen('Data Summary - Resistivity.txt','a'); 
             
            Header={'File Name','Test Time','Measurement Mode','n Cycles',... 
                    'R(P-P) Mean','R(P-P) Std Dev',... 
                    'R(RMS) Mean','R(RMS) Std Dev',... 
                    'FFT Integ Width (Hz)','R(FFT)'}; 
            for i=1:length(Header) 
                fprintf(fid,'%s',Header{i}); 
                if i<length(Header) 
                    fprintf(fid,'\t'); 
                else 
                    fprintf(fid,'\r\n'); 
                end 
            end 
        else 
            fid=fopen('Data Summary - Resistivity.txt','a'); 
        end 
         
        fprintf(fid,strcat(filename{f},'\t',testtime,'\t')); 
        if strcmp(MeasMode(1:3),'R2E') 
            fprintf(fid,'2\t'); 
        else 
            fprintf(fid,'4\t'); 
        end 
        fprintf(fid,'%i\t',length(R_PP)); 
        fprintf(fid,'%g\t%g\t',mean(R_PP),std(R_PP)); 
        fprintf(fid,'%g\t%g\t',mean(R_RMS),std(R_RMS)); 
        fprintf(fid,'%g\t%g\r\n',int_width_Hz,R_FFT); 
        fclose(fid); 
         
        %---------------------------------------------- 
        % Save Figure to image file 
        %---------------------------------------------- 
        orient landscape 
        disp('Generating Image...') 
        print(1,'-dtiff','-r300',filename{f}) 
        disp('Rotating image...') 
        X=imread(filename{f},'tiff'); 
        X=imrotate(X,270); 
        disp('Writing Image...') 
        imwrite(X,strcat(filename{f},'.tif'),'tiff'); 
        disp('Done') 
        beep 
    end 
  
end 
 
%=================================================== 
% CONDUCTION VELOCITY 
%=================================================== 
if strcmp(MeasMode,'CV') 
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    %---------------------------------------------- 
    % Calibrate Ih, Vh, E2, and E4 
    %---------------------------------------------- 
    Ih=1000*data(1,:)/Gain_I/R_Sense; 
    Vh=1000*data(2,:)/Gain_V; 
    E2=1000*data(3,:)/Gain_E2; 
    E4=1000*data(4,:)/Gain_E4; 
 
    %---------------------------------------------- 
    % Find Pulses   
    %---------------------------------------------- 
    if (max(Ih)-mean(Ih))>(mean(Ih)-min(Ih)) 
        % Pulses are positive 
        Thresh_I=mean(Ih)+0.8*(max(Ih)-mean(Ih)); 
        z=Ih>Thresh_I; 
    else 
        % Pulses are negative 
        Thresh_I=mean(Ih)+0.8*(mean(Ih)+min(Ih)); 
        z=Ih<Thresh_I; 
    end 
     
    % x=1 at start time, y=1 at stop time 
    x=[0 diff(z)]>0; 
    y=[diff(z) 0]<0; 
     
    StimIndex(:,1)=find(x)'; 
    StimIndex(:,2)=find(y)'; 
     
    % Make sure last index is sufficiently far from end of record 
    t_PreStim=0.005;    % time before stim to include (in seconds) 
    t_Width=0.205;      % total window length to include (in seconds) 
     
    % Remove last stim from array if window length would extend past end of data 
    if StimIndex(length(StimIndex),1) > (length(Ih)-(t_Width-t_PreStim)*scanrate-1) 
        StimIndex=StimIndex(1:(length(StimIndex)-1),:) 
    end 
     
    % Calculate Stim Times, Stim Durations, Stim Intervals, and Stim Amplitudes 
    StimTime=time(StimIndex(:,1)); 
    StimDur=time(StimIndex(:,2))-StimTime; 
    StimInt=[0 diff(StimTime)]; 
    for i=1:size(StimIndex,1) 
        StimAmplitude(i)=mean(Ih(StimIndex(i,1):StimIndex(i,2)))-mean(Ih); 
    end 
     
    %---------------------------------------------- 
    % Find Activation 
    %---------------------------------------------- 
    boxwidth=10; 
    fb=ones(1,boxwidth); 
    fa=zeros(1,boxwidth); 
    fa(1)=boxwidth; 
    filtVh=filtfilt(fb,fa,Vh); 
    filtE2=filtfilt(fb,fa,E2); 
    filtE4=filtfilt(fb,fa,E4); 
     
    for i=1:length(StimTime) 
        Start=StimIndex(i,2)+0.005*scanrate; 
        Stop=Start+0.150*scanrate; 
         
        if Stop>=length(Vh) 
            Stop=length(Vh)-1; 
        end 
        Vh2=filtVh(Start:Stop); 
         
        x=Vh2-mean(Vh2(1:100)); 
%         x=[diff(Vh2) 0]; 
%         x=abs(x); 
%         x=-x;    
        y=x>=max(x); 
        z=find(y); 
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        z=z(1); 
 
        ActivIndex(i)=z+Start-1; 
        ActivTime(i)=time(ActivIndex(i));  
    end 
     
     
    %---------------------------------------------- 
    % Signal Averaging 
    %---------------------------------------------- 
    j=0; 
    for i=1:length(StimIndex) 
        Start=StimIndex(i,1)-t_PreStim*scanrate; 
        Stop=Start+t_Width*scanrate; 
        if or(Start<0,Stop>length(Vh))~=1 
            j=j+1; 
            IhSigAvg{1}(j,:)=Ih(Start:Stop); 
            VhSigAvg{1}(j,:)=filtVh(Start:Stop); 
            E2SigAvg{1}(j,:)=filtE2(Start:Stop); 
            E4SigAvg{1}(j,:)=filtE4(Start:Stop); 
        end 
    end 
    IhSigAvg{2}=mean(IhSigAvg{1},1); 
    VhSigAvg{2}=mean(VhSigAvg{1},1); 
    E2SigAvg{2}=mean(E2SigAvg{1},1); 
    E4SigAvg{2}=mean(E4SigAvg{1},1); 
     
    %---------------------------------------------- 
    % Calculate Delay Time 
    %---------------------------------------------- 
    ActivDelay=ActivTime-StimTime; 
    DelayMean=mean(ActivDelay); 
    DelayStDev=std(ActivDelay); 
     
     
    %---------------------------------------------- 
    % Calculate Y-Limits for Plots 
    %---------------------------------------------- 
 
    SrchIndx=[ceil((max(StimDur)+t_PreStim+0.005)*scanrate):length(IhSigAvg{2})]; 
    MarginMin=0.15; 
    MarginMax=0.3; 
     
    % Ih 
    Y_Limits{1,1}=[min(Ih)-0.075*(max(Ih)-min(Ih)) max(Ih)+0.075*(max(Ih)-min(Ih))]; 
    Y_Limits{1,2}=Y_Limits{1,1}; 
     
    % Vh 
    if min(Vh)<max(Vh) 
        Y_Limits{2,1}=[min(Vh)-0.075*(max(Vh)-min(Vh)) max(Vh)+0.075*(max(Vh)-min(Vh))]; 
        a=min(min(VhSigAvg{1}(:,SrchIndx))); 
        b=max(max(VhSigAvg{1}(:,SrchIndx))); 
        Y_Limits{2,2}=[a-MarginMin*(b-a) b+MarginMax*(b-a)]; 
    else 
        Y_Limits{2,1}=[min(Vh)-1 min(Vh)+1]; 
        Y_Limits{2,2}=Y_Limits{2,1}; 
    end 
     
    % E2 
    if min(E2)<max(E2) 
        Y_Limits{3,1}=[min(E2)-0.075*(max(E2)-min(E2)) max(E2)+0.075*(max(E2)-min(E2))]; 
        a=min(min(E2SigAvg{1}(:,SrchIndx))); 
        b=max(max(E2SigAvg{1}(:,SrchIndx))); 
        Y_Limits{3,2}=[a-MarginMin*(b-a) b+MarginMax*(b-a)]; 
    else 
        Y_Limits{3,1}=[min(E2)-1 min(E2)+1]; 
        Y_Limits{3,2}=Y_Limits{3,1}; 
    end 
     
    % E4 
    if min(E4)<max(E4) 
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        Y_Limits{4,1}=[min(E4)-0.075*(max(E4)-min(E4)) max(E4)+0.075*(max(E4)-min(E4))]; 
        a=min(min(E4SigAvg{1}(:,SrchIndx))); 
        b=max(max(E4SigAvg{1}(:,SrchIndx))); 
        Y_Limits{4,2}=[a-MarginMin*(b-a) b+MarginMax*(b-a)]; 
    else 
        Y_Limits{4,1}=[min(E4)-1 max(E4)+1]; 
        Y_Limits{4,2}=Y_Limits{4,1}; 
    end 
     
    %---------------------------------------------- 
    % Plot All Data Channels Together 
    %---------------------------------------------- 
    figure(1) 
    LabelFontSize=8; 
    t=1000*(time(1:length(IhSigAvg{2}))-t_PreStim); 
    for i=1:4 
        if i==1 
            Y_Lbl='Ih (mA)'; 
            Y=Ih; 
            Y1=IhSigAvg{1}; 
            Y2=IhSigAvg{2}; 
            X_Lbl_1=' '; 
            X_Lbl_2=' '; 
            Title_1=strrep(strcat(filename{f},'________',testtime),'_',' '); 
            Title_2='Signal Averaged'; 
        elseif i==2 
            Y_Lbl='Vh (mV)'; 
            Y=Vh; 
            Y1=VhSigAvg{1}; 
            Y2=VhSigAvg{2}; 
            X_Lbl_1=' '; 
            X_Lbl_2=' '; 
            Title_1=' '; 
            Title_2=' '; 
        elseif i==3 
            Y_Lbl='E2 (mV)'; 
            Y=E2; 
            Y1=E2SigAvg{1}; 
            Y2=E2SigAvg{2}; 
            X_Lbl_1=' '; 
            X_Lbl_2=' '; 
            Title_1=' '; 
            Title_2=' '; 
        elseif i==4 
            Y_Lbl='E4 (mV)'; 
            Y=E4; 
            Y1=E4SigAvg{1}; 
            Y2=E4SigAvg{2}; 
            X_Lbl_1='Time (sec)'; 
            X_Lbl_2='Time (msec)'; 
            Title_1=' '; 
            Title_2=' '; 
        end 
         
        % Column 1: Entire Record 
        subplot(4,2,2*i-1) 
        plot(time,Y); 
        xlim([min(time) max(time)]) 
        ylim(Y_Limits{i,1}) 
        ylabel(Y_Lbl,'FontSize',LabelFontSize) 
        xlabel(X_Lbl_1,'FontSize',LabelFontSize) 
        title(Title_1,'FontSize',LabelFontSize) 
        set(gca,'FontSize',LabelFontSize) 
         
        % Column 2: Signal Avg 
        subplot(4,2,2*i) 
        hold on; 
        plot(t,Y1,'b','LineWidth',0.25) 
        plot(t,Y2,'k','LineWidth',1.5) 
        hold off; 
        box on 
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        ylim(Y_Limits{i,2}) 
        xlim([min(t) max(t)]) 
        ylabel(Y_Lbl,'FontSize',LabelFontSize) 
        xlabel(X_Lbl_2,'FontSize',LabelFontSize) 
        title(Title_2,'FontSize',LabelFontSize) 
        set(gca,'FontSize',LabelFontSize) 
         
        % Mark Stim Strength 
        if i==1 
            a=mean(StimAmplitude); 
            b=std(StimAmplitude); 
            c=length(StimAmplitude); 
             
            text((min(get(gca,'xlim'))+0.95*diff(get(gca,'xlim'))),... 
                (min(get(gca,'ylim'))+0.90*diff(get(gca,'ylim'))),... 
                strrep(strcat(num2str(a,'%.2f'),' \pm_',num2str(b,'%.2f'),... 
                ' mA (n=',num2str(c),')'),'_',' '),... 
                'HorizontalAlignment','right','VerticalAlignment','middle',... 
                'FontSize',LabelFontSize) 
        end 
         
        % Mark activation time 
        Capturing=1; 
        if Capturing==1; 
            hold on; 
            plot(mean(1000*ActivDelay)*[1 1],get(gca,'YLim'),'--k','LineWidth',0.25) 
            if i==2 
                plot(mean(1000*ActivDelay),mean(filtVh(ActivIndex)),... 
                    'r+','LineWidth',1.5,'MarkerSize',5) 
                plot([0 mean(1000*ActivDelay)],(min(get(gca,'ylim'))+... 
                    0.05*diff(get(gca,'ylim')))*[1 1],'r','LineWidth',2) 
                a=mean(1000*ActivDelay); 
                b=std(1000*ActivDelay); 
                c=length(ActivDelay); 
                text((min(get(gca,'xlim'))+0.95*diff(get(gca,'xlim'))),... 
                    (min(get(gca,'ylim'))+0.90*diff(get(gca,'ylim'))),... 
                    strrep(strcat(num2str(a,'%.2f'),' \pm_',num2str(b,'%.2f'),... 
                        ' ms (n=',num2str(c),')'),'_',' '),... 
                        'HorizontalAlignment','right','VerticalAlignment','middle',... 
                        'FontSize',LabelFontSize) 
            end 
            hold off; 
        else 
            if i==2 
                text((min(get(gca,'xlim'))+0.95*diff(get(gca,'xlim'))),... 
                    (min(get(gca,'ylim'))+0.90*diff(get(gca,'ylim'))),... 
                    'NOT CAPTURING',... 
                    'HorizontalAlignment','right','VerticalAlignment','middle',... 
                    'FontSize',LabelFontSize) 
            end 
        end 
         
    end 
     
     
    %---------------------------------------------- 
    % Plot Vh, E2/E3, and E4 
    %---------------------------------------------- 
    for i=2:4 
        if i==2 
            Y=Vh; 
            filtY=filtVh; 
            Y_Lbl='Vh (mV)'; 
        elseif i==3 
            Y=E2; 
            filtY=filtE2; 
            Y_Lbl='E2 (mV)'; 
        elseif i==4 
            Y=E4; 
            filtY=filtE4; 
            Y_Lbl='E4 (mV)'; 
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        end 
         
        % PLOT SETTINGS 
        figure(i); 
        clf(i); 
        LabelFontSize=8; 
        col=5; 
        row=2+ceil(length(StimTime)/col); 
         
        % SUBPLOT 1: Stimulus Current (Ih) for entire record length 
        subplot(row,col,1:col); 
        plot(time,Ih,'b') 
        ylim(Y_Limits{1,1}) 
        title(strrep(strcat(filename{f},'________',testtime),'_',' ')) 
        ylabel('Ih (mA)','FontSize',LabelFontSize) 
        set(gca,'FontSize',LabelFontSize) 
            
        % SUBPLOT 2: Voltage (Vh, E2/E3, or E4) for entire record length 
        subplot(row,col,(col+1):(col*2)); 
        plot(time,filtY) 
        ylim(Y_Limits{i,1}) 
        ylabel(Y_Lbl,'FontSize',LabelFontSize) 
        set(gca,'FontSize',LabelFontSize) 
         
         
        % REMAINING SUBPLOTS: Voltage (Vh, E2/E3, or E4) for individual beats 
        for j=1:length(StimTime); 
            subplot(row,col,(col*2+j)) 
             
            % Define start and stop indices for subplots 
            Start=StimIndex(j,1)-t_PreStim*scanrate; 
            Stop=Start+t_Width*scanrate; 
            if Stop>length(Y) 
                Stop=length(Y); 
            end 
             
            % New arrays for individual beat segment 
            t=time(Start:Stop); 
            Y2=filtY(Start:Stop); 
             
            % X Limits 
            X_Limits=[min(t) min(t)+t_Width]; 
             
            % Plot individual beat 
            plot(t,Y2,'k','LineWidth',1) 
            ylim(Y_Limits{i,2}) 
            xlim(X_Limits) 
            set(gca,'FontSize',6) 
             
            % Indicate delay time 
            NotCapturing=[0]; 
            if sum(j==NotCapturing)==0 
                hold on; 
                plot(ActivTime(j),filtY(ActivIndex(j)),'r+','LineWidth',1,'MarkerSize',5) 
                plot([StimTime(j) ActivTime(j)],(min(get(gca,'ylim'))+... 
                    0.05*diff(get(gca,'ylim')))*[1 1],'r','LineWidth',2) 
                hold off; 
                 
                text((min(get(gca,'xlim'))+0.95*diff(get(gca,'xlim'))),... 
                    (min(get(gca,'ylim'))+0.90*diff(get(gca,'ylim'))),... 
                    strcat(num2str(1000*ActivDelay(j),'%.1f'),'ms'),... 
                        'HorizontalAlignment','right','VerticalAlignment','middle',... 
                        'FontSize',LabelFontSize) 
            else 
                text((min(get(gca,'xlim'))+0.5*diff(get(gca,'xlim'))),... 
                    (min(get(gca,'ylim'))+0.85*diff(get(gca,'ylim'))),... 
                    'NOT CAPTURING',... 
                    'HorizontalAlignment','center','VerticalAlignment','middle',... 
                    'FontSize',LabelFontSize) 
            end 
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            % Add Y Axis Labels 
            if rem((col*2+j),col)==1 
                ylabel(Y_Lbl,'FontSize',LabelFontSize) 
            end 
             
            % Add X Axis Labels 
            if (col*2+j)>(row*col-col) 
                xlabel('Time (s)','FontSize',LabelFontSize) 
            end 
        end 
    end 
     
    %---------------------------------------------- 
    % Make Summary Data Array 
    %---------------------------------------------- 
     
    DataSummary(1,:)=[1:length(StimTime)]; 
    DataHeader{1,1}='Beat'; 
    DataHeader{1,2}='n'; 
     
    DataSummary(2,:)=StimTime; 
    DataHeader{2,1}='Stim Time'; 
    DataHeader{2,2}='(sec)'; 
     
    DataSummary(3,:)=1000.*[0 diff(StimTime)]; 
    DataHeader{3,1}='Stim Interval'; 
    DataHeader{3,2}='(msec)'; 
     
    DataSummary(4,:)=1000*StimDur; 
    DataHeader{4,1}='Stim Duration'; 
    DataHeader{4,2}='(msec)'; 
     
    DataSummary(5,:)=StimAmplitude; 
    DataHeader{5,1}='Stim Amplitude'; 
    DataHeader{5,2}='(mA)'; 
     
    DataSummary(6,:)=ActivTime; 
    DataHeader{6,1}='Activation Time'; 
    DataHeader{6,2}='(sec)'; 
     
    DataSummary(7,:)=1000*ActivDelay; 
    DataHeader{7,1}='Activation Delay'; 
    DataHeader{7,2}='(msec)'; 
     
    %---------------------------------------------- 
    % Write to File? 
    %---------------------------------------------- 
    write_to_file=input('Write to File? (Y/N): ','s'); 
    if strcmp(lower(write_to_file),'y')==1 
        write_to_file=1; 
    else 
        write_to_file=0; 
    end 
     
    if write_to_file==1 
        %---------------------------------------------- 
        % Write to File 
        %---------------------------------------------- 
        fid=fopen('Data Summary - Conduction Velocity.txt','a'); 
        fprintf(fid,strcat(filename{f},'\t\t\t\t\t\t',testtime,'\r\n')); 
        for j=1:size(DataHeader,2) 
            for i=1:size(DataHeader,1) 
                if i~=1 
                    fprintf(fid,'\t'); 
                end 
                fprintf(fid,'%s',DataHeader{i,j}); 
            end 
            fprintf(fid,'\r\n'); 
        end 
         
        for j=1:size(DataSummary,2) 
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            for i=1:size(DataSummary,1) 
                if i~=1 
                    fprintf(fid,'\t'); 
                end 
                if and(i==3,j==1)~=1 
                    fprintf(fid,'%f',DataSummary(i,j)); 
                end 
            end 
            fprintf(fid,'\r\n'); 
        end 
         
        for i=1:size(DataSummary,1) 
            if i==1 
                fprintf(fid,'Mean'); 
            elseif i==3 
                fprintf(fid,'\t%f',mean(DataSummary(i,2:size(DataSummary,2)))); 
            elseif or(i==2,i==6) 
                fprintf(fid,'\t'); 
            else 
                fprintf(fid,'\t%f',mean(DataSummary(i,:))); 
            end 
        end 
 
        for i=1:size(DataSummary,1) 
            if i==1 
                fprintf(fid,'\r\nSt Dev'); 
            elseif i==3 
                fprintf(fid,'\t%f',std(DataSummary(i,2:size(DataSummary,2)))); 
            elseif or(i==2,i==6) 
                fprintf(fid,'\t'); 
            else 
                fprintf(fid,'\t%f',std(DataSummary(i,:))); 
            end 
        end 
 
        fprintf(fid,'\r\n\r\n'); 
         
        fclose(fid); 
         
        %---------------------------------------------- 
        % Save Figure to image file 
        %---------------------------------------------- 
         
        PlotName{1}='1-All Traces'; 
        PlotName{2}='2-Vh'; 
        PlotName{3}='3-E2'; 
        PlotName{4}='4-E4'; 
         
        for i=1:4 
            figure(i) 
            orient landscape 
            disp(strrep(strcat('Generating Image_',num2str(i),'_of 4...'),'_',' ')) 
            print(i,'-dtiff','-r300',strcat(filename{f},'-',PlotName{i})) 
            disp(strrep(strcat('Rotating Image_',num2str(i),'_of 4...'),'_',' ')) 
            X=imread(strcat(filename{f},'-',PlotName{i}),'tiff'); 
            X=imrotate(X,270); 
            disp(strrep(strcat('Writing Image_',num2str(i),'_of 4...'),'_',' ')) 
            imwrite(X,strcat(filename{f},'-',PlotName{i},'.tif'),'tiff'); 
        end 
        disp('Done') 
        beep 
    end 
end 
 
disp(strrep(strcat('Elapsed Time:_',num2str(floor(toc/60)),':',... 
     num2str(round(rem(toc,60)))),'_',' ')) 
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